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8.1

INTRODUCTION

The presence of active pharmaceuticals ingredients (APIs) in aquatic systems has led in recent
years to a burgeoning literature examining environmental occurrence, fate, effects, risk assessment,
and treatability of these compounds. The vast preponderance of studies aimed at identifying and
quantifying contaminant residues in aquatic tissues have involved the conventional and legacy pollutants. Comparatively few studies have been targeted at APIs, primarily those that are lipophilic.
Although APIs have received much attention as "emerging" contaminants of concern, it is important to recognize that traditional approaches to understand and predict exposure and effects of other
environmental organic contaminant classes mayor may not be appropriate for APIs. For example, traditional approaches for understanding aquatic effects may not be as useful for some APIs
(Brooks et al. 2003), but lessons learned from the study of compounds active at the hypothalamicpituitary-gonadal axis (endocrine disruptors/modulators) may reduce uncertainties associated with
environmental assessments of other APIs (Ankley et al. 2007).
Whereas APIs are often considered as a combined class of environmental contaminants,
APIs include diverse groups of chemicals with physiochemical properties ranging in pharmacological potencies, environmental fate profiles, and patient usage patterns. Due to the relatively
rudimentary state of knowledge for aquatic exposures to these substances, an understanding of
critical body residues (CBRs) necessary to elicit pharmacologically and ecologically relevant
responses is not available at this time. Because exposure does not necessarily evoke effects or
risk, current challenges include understanding the relationship between exposure and effects
within an ecological risk assessment framework. It appears particularly critical to understand
whether internal pharmacological doses of APls in target tissues result from exposures at environmentally relevant or realistic concentrations. Such information can inform ecological risk
assessments examining the potential effects of APls based on their specific mechanism/mode
of action (MOA).
Tissue residues of contaminants are commonly used in retrospective ecological risk assessments
to support an understanding of environmental exposure (Suter et al. 2000). Bioconcentration factors
(BCFs) are useful in both retrospective and prospective assessments of traditional contaminants;
BCFs are expressed as the ratios of concentrations in tissues (mass/kg) and the respective concentrations in the surrounding aqueous compartment (mass/L), resulting in units of Llkg. APIs are
conceptually no different from these conventional contaminants because tissue residues can provide
important information in exposure analysis, particularly when used as indicators of exposure in
the field. Whole-body and tissue concentrations are essentially proxies for gauging the actual dose
at the site(s) of action, which mayor may not be known. When bioconcentration occurs, an obvious advantage of measuring internal concentrations is when the external concentrations are below
method detection limits (MDLs).
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Compared with many conventional pollutants, APTs are in general comparatively more polar.
They therefore tend to not partition to particulates and sediments, but rather remain dissolved in
he aqueOUS phase. For those APIs that have significant tendency to become sediment-bound, little
t ttention has been given to their bioavailability as measured by bioaccumulation. The measure of
~ioaccumulation of a chemical associated with sediment is the biota-sediment accumulation factor
(BSAF). The BSAF is expressed as a chemical's tissue concentration normalized to lipid content
relative to its concentration normalized to sediment total organic carbon (Burkhard 2009).
In this chapter we examine relevant information on residues in aquatic organisms, select factors
influencing exposure, and available methods to understand relationships between exposure scenarios and effects thresholds. Though APIs are often combined with discussions of personal care
products (PCPs) in the literature that has rapidly developed following publication of Daughton and
Ternes (1999), we specifically focus on APIs for the purposes of this chapter. A broad literature on
pCPs in aquatic organisms continues to develop (e.g., Mottaleb et al. 2009) and was recently summarized by Ramirez (2007).
An insight of particular importance concerns the level of knowledge regarding the linkage between
exposure to APIs and adverse effects in aquatic organisms. Regardless of the available published
data on exposure of aquatic organisms to APIs (and its size is indeed very limited, especially for
real-world scenarios), it rarely intersects a complementary body of data for biological effects. When
exposure data do exist, the same conditions, concentrations, and species have rarely been used in
toxicity studies; parallel data sets are also usually disconnected temporally. Likewise, a considerable
body of API data exists for effects, but exposure conditions (especially the API concentration or route
of exposure) are often not environmentally realistic. The ability to routinely connect real-world API
occurrence data to documented biological effects is therefore not yet available. Evidence for causality
is probably strongest for sex steroids, largely because of their ubiquity and potencies; but even here,
evidence can be confusing (e.g., see Vogeli 2008). A major challenge in establishing causality-a
lack of correlation between tissue levels and observed effects-could well be the result of delayed
effects, such as those only manifesting at later life stages but originating from exposure at earlier
developmental stages; this is especially true for organisms with longer life cycles.

8.2
8.2.1

EXPOSURE
BACKGROUND

The published literature on APIs as environmental contaminants is dominated with data on the
analysis, occurrence, and fate of these chemicals in the environment, together with evaluation
of waste and water treatment technologies. Surprisingly, comparatively little has been published
regarding the aquatic toxicology of APIs, especially data relevant to exposure. Little information is
available, for example, on the occurrence of APIs in aquatic organisms. This in itself is surprising
given that predictive models for bioconcentration in fish are not yet up to the task, and empirical
data are needed at least to validate computational approaches. The complexities and limitations of
modeling bioconcentration of conventional pollutants (especially the legacy pollutants) in fish are
discussed in detail by a number of authors (e.g., Geyer et a1. 2000, Gobas and Morrison 2000, Van
der Oost et a1. 2003, Nichols et a1. 2007).
The bulk of the studies on drug residues in aquatic tissues relate to what is known from aquaculture, where exposure is restricted to a very limited number of drugs (almost all being veterinary
drugs) and at concentrations orders of magnitude higher than might occur in the ambient environment. Of the thousands of published studies that have been compiled regarding the many aspects
of APIs as environmental pollutants (U.S. EPA 2009), roughly only 50 or so are directly relevant
to aquatic exposure and tissue levels of APIs, and the majority of these studies have been published
since Brooks et al. (2005) reported fish tissue residues of SSRIs (selective serotonin reuptake inhibitors) from an effluent-dominated stream.
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APIs have long been assumed to show little propensity to bioconcentrate, no less biomagnify,
This has been based largely on their greater water solubility compared with conventional pollutants such as pesticides and many industrial pollutants, especially the persistent organic pollutants
(POPs). But APIs are known to sometimes undergo active transport, so this assumption may not be
valid. Little is known for assisting the assessment of the bioaccumulation potential in fish (CowanEllsberry et al. 2008); even less is known regarding the bioconcentration of APIs by fish or other
aquatic organisms. Bioaccumulation is deemed possible when the BCF (expressed as Llkg) exceeds
a range of 500-5000, depending on the standard being applied (Cowan-Ellsberry et al. 2008).
Even when definitive data have been obtained regarding bioconcentration, whether this can be
extrapolated among species is unknown. Owen et al. (2007) emphasize the diversity in biology
among the 28,000 species of fish. Tissue levels are governed largely by the pharmacokinetics of
the API. These authors also point out that almost nothing is known regarding the pharmacokinetics
of APIs in aquatic organisms-the xenoestrogen 17a-ethinyl estradiol (EE2) being one exception.
Also, while it might be useful, extrapolations between mammals and fish can be challenging and
potentially misleading because of key differences in physiology. Owen et al. (2007) stress that a primary route of uptake in fish is via the gills, from where blood is delivered to various organs before
reaching the liver, in contrast to oral exposure in mammals, which leads to first-pass metabolism
in the liver. Yet a further complication is the wide disparity that can exist among reported K"w data
for a particular API; the ~,W is the octanol-water partition coefficient-the ratio of a chemical's
equilibrium concentration in octanol versus water at a defined temperature. These values can range
over several orders of magnitude, pointing to the need for empirical data with which to validate
and develop better predictive models. As discussed later, site-specific pH can influence the ionization state of many APIs, reducing the utility of using Kow to predict exposure in retrospective
evaluations; methodologies for estimating the BCFs for organic electrolytes have been assessed by
Fu et al. (2009).
Exposure is a term commonly used by toxicologists, modelers, and others involved with environmental science. Exposure is a key component of the risk assessment paradigm that can provide
insights for ways to reduce biological effects as well as better understand or predict their potential
for occurring. Exposure translates the potential of hazard into the reality of risk (see Figure 8.1).
But defining what is actually meant by exposure poses significant challenges. It does not necessarily represent a discrete physical or temporal point in the complex series of events that determine
the outcomes from physical contact of an organism with a chemical or other stressor. Rather, the
processes involved with exposure are spread across a complex spatiotemporal continuum that links
a stressor's source or origin with the eventual effects that might occur within biological systems.
Although exposure includes understanding the duration, frequency, and magnitude to which
organisms interact with biologically available contaminants, exposure magnitude is available for
a limited number of APIs, and exposure duration and frequency is largely unknown for all APIs.
Exposure is usually shown in conceptual diagrams as a standalone part of the hazard-risk continuum, an example being shown in Figure 8.1. External factors may influence the bioavailability,
absorption, and uptake of an API, while physiochemical properties of an API influences pharmacological bioavailability, and internal factors (e.g., metabolism) will influence the duration of internal
dosimetry. Chemical exposure is often visualized as the physicochemical interaction of a biological
receptor with the chemical stressor, as when a ligand binds with a receptor. In practice, however,
separating exposure from effects can be arbitrary and at times confusing. This is especially true
when discussing biomarkers of exposure and biomarkers of effects.
A biomarker can be defined as pathway- or receptor-specific observations that are chemical-induced responses at the biochemical, physiological, or morphological level of an organism
(Committee on Biological Markers of the National Research Council 1987). In ecotoxicology, biomarkers represent critical measures to support an understanding of exposure and potential effects
to environmental contaminants. Under prospective and retrospective ecological risk assessment
frameworks, it is useful to classify the various sublethal responses organisms may exhibit following
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FIGURE 8.1 Source-to-effects continuum generalized for chemical stressors (but all principles also apply to
APls). The rounded rectangular boxes represent major points or processes in time or space along the sourceto-effects continuum . The ovalized rectangular boxes and arrow labels represent variables that affect the
processes along the continuum. The SCALE arrow represents the level of biological organization that the
stressor impacts.

exposure to contaminants as either biomarkers of exposure or biomarkers of effect (Huggett et al.
1992). Biomarkers of exposure differ from biomarkers of effect in that these measures inform
whether an organism has been exposed to contaminants (e.g., gene expression) but do not necessarily
allow for determination of whether the organism has been adversely impaired. Biomarkers of effect
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(e.g., egg shell thinning, histopathology), however, are indicators of ecotoxicity, especially when
measures of an adverse effect can be linked to a physiologically and ecologically relevant endpoint
(e.g., growth) with population-level relevance (Ankley et al. 2007, Brain et al. 2008a). Biomarkers
of exposure and effect have been successfully employed in a variety of retrospective ecological risk
assessments (Suter et al. 2000), and their use in prospective environmental risk assessment is projected to increase due to a number of factors. Environmental contaminants such as APIs that may
exert toxicity through receptor/enzyme interactions are providing an impetus toward "intelligent"
ecotoxicity testing, which requires development and interpretation of biomarkers.
Regardless of the difficulty in providing a rigorous definition of exposure, the general concept
of exposure is essential for organizing discussions about assessing risk. In this chapter, we use exposure as the framework to better understand the ramifications of APIs in the aquatic environment.
After all, in the absence of exposure, hazard cannot translate into risk. Likewise, exposure does
not necessarily pose ecologically relevant risk levels-for example, if perturbation of homeostasis
does not result.
The prime aspect of exposure that creates the potential for a cascade of events within biological
systems is the initial physical association or interaction of chemical stressors with an organism. In
the aquatic environment, a prime sign of exposure is the simple occurrence of a stressor within one
or more tissues, such as blood, lipid, muscle, bile, liver, ovaries, eggs, or brain. The factors driving
the partitioning and distribution of APIs within fish are incompletely understood. For example,
fish have a variety of chromatophores, some of which are pigment-containing, such as melanocytes (New World Encyclopedia contributors August 13, 2008). During development, pigmented
melanocytes begin appearing within a day of fertilization. The potential significance of these cells
to exposure is related to their high binding affinities for a broad spectrum of xenobiotics, including
a wide array of APls known for high affinity to melanin (Testorf et al. 2001, Aubry 2002, Roffey
et al. 2007). Since humans only have melanocyte chromatophores, melanin has been most studied.
Binding to melanin is known to lead to drug accumulation, one of the routes resulting in the concentration of drugs in hair (Larsson 1993). In fish, binding to melanin (and possibly to other pigments)
could lead to API reservoirs within certain tissues.
APIs introduced to the aquatic environment via sewage pose additional challenges in assessing
exposure. Because of extreme spatiotemporal fluctuations in concentrations, how accurately can
exposure be assessed on the basis of monitoring residues in water? This is especially true for APIs
that are released episodically, whether event-driven (such as by the sporadic practice of disposal) or
when discharged by diurnal patterns in flushing of sewers or when influenced by seasonality (which
can affect waste treatment efficiency as well as the types and quantities of individual APIs that are
being used). These factors can result in high but transient concentrations, strongly influencing exposure magnitude, duration, and frequency (Daughton 2007). Traditional sampling using discrete grab
samples may not be representative of longer term exposure levels. Passive, integrative samplers can
overcome some of these limitations (e.g., Vermeirssen et al. 2008), though the applicability has not
been demonstrated for a broad range of APls, and samplers do not characterize all routes of exposure (e.g., dietary).
A body of published work points to a spectrum of potential toxicological consequences following controlled exposure of certain aquatic organisms to a limited number of APls, but these studies
ignore whether real-world exposures actually occur and whether they occur at the requisite realistic concentrations (e.g., Gaworecki and Klaine 2008). Often, effects using traditional endpoints
(e.g., survival, growth, and reproduction) in traditional test species (e.g., Ceriodaphnia dubia) are
found only at levels orders of magnitude higher than known in the environment (e.g., Henry and
Black 2008). Such observations are generally supported by several recent papers that reviewed
information on aquatic toxicity of APIs (Crane et al. 2006, Fent et al. 2006, Farre et al. 2008).
Rather than repeating such efforts here, it is instead important to keep in mind that the effects
level is a function of the sensitivity of the targeted endpoint in the test species selected for study;
other endpoints-especially those still not recognized-may have lower effective concentrations
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(below current NOAELs-no observable adverse effect levels), particularly from standardized
ecotoxicity assays.
Determining whether a more sensitive endpoint represents an ecologically relevant measure of
effect amenable to inclusion in effects analysis of an ecological risk assessment must be considered
for APIs (Ankley et al. 2007). For example, the ecologically relevant fathead minnow reproduction
and feeding behavior endpoints are more sensitive to EE2 (Ankley et al. 2001) and ftuoxetine (Stanley
et al. 2007), respectively, than 7-day juvenile fathead minnow growth, which is routinely employed
prospectively to assess sublethal effects of individual chemicals, ambient toxicity in surface waters,
and whole-effluent toxicity. Other endpoints, which may represent ecologically relevant biomarkers
of effect, should be mechanistically linked to ecologically relevant endpoints (Ankley et al. 2007)
that can be integrated in ecological risk assessments (Brooks et al. 2009b). One recent example
of an ecologically relevant and more sensitive endpoint than traditional morphometric responses
(e.g., growth) was presented by Brain et al. (200Sb). Disruption of the folate biosynthetic pathway
in aquatic plants was demonstrated following sublethal exposure to sulfamethoxazole at concentrations more than an order of magnitude lower than for growth impairment (Brain et al. 200Sb).
Why should we care about exposure? Better understanding of exposure provides the opportunity
to look both backward and forward in the hazard-risk continuum-ranging from sources to effects.
Measurement of exposure can be used in a retrospective ecological risk assessment, for example,
to reveal sources of contamination, measure site-remediation success, as a surrogate measure of
contaminant concentrations, or to reconstruct dose, or in a prospective ecological risk assessment to
estimate the possibility of disease and its time of onset. Some of the major reasons for understanding and measuring exposure in the aquatic environment are captured in Table S.l.

TABLE 8.1
The Importance of Understanding or Measuring Aquatic Exposure
Aquatic Exposure Data Can Be
Used For

Rationale

Advanced warning of effects

Measure potential for adverse population-level effects or individual effects (in the
case of threatened and endangered species), should the level of exposure be
sustained or rise, or should the onset of effects be delayed.

Prognosis or vulnerability

Predict the likelihood of, or vulnerability for, future disease onset should exposure
occur.

Reveal potential for subtle effects
Prioritization of APIs

Provide insights on the potential for cumulative subtle etfects that might go
unnoticed until a level of irreversible harm has been reached.
Exposure studies can inform, direct, and guide the selection of APIs for more
in-depth toxicological study; likewise, occurrence studies (such as from water
monitoring), can be used to guide exposure studies.

Reveal inadeq uacieslflaws in
models

Bioconcentrated/bioaccumulated body burdens often do not comport with
predictive models (e.g., Maunder et al. 2007).

Reveal potential for food chain
disturbances

When bioconcentration and bioaccumulation resist predictive modeling, analysis of
tissue levels are therefore required.

Sentinel for terrestrial organism
exposure

Being more susceptible to exposure than terrestrial organisms and for development
of subtle effects, aquatic exposure can serve as a sentinel model for terrestrial
exposures (such as might occur from the recycling of treated sewage).

Potential for human exposure

Can provide information on levels of potential stressors that humans might
consume via the food chain (e.g., contaminated fish in the diet).

Corroborate representativeness or
need for toxicity testing

Establish whether concentrations/doses used in toxicity testing actually occur in
the wild.

continued
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TABLE 8.1 (continued)
The Importance of Understanding or Measuring Aquatic Exposure
Aquatic Exposure Data Can Be
Used For
Stressor sources/origins/
distributions
Pollution prevention/source control
Gauge success/progress of cleanup
or remediation efforts, or of new
waste treatment technologies
Surrogate measure of pollutant
concentrations
Inadequacy in water monitoring for
predicting exposure

Magnify levels of stressors not
ordinarily toxic
Magnify levels of stressors not
ordinarily detectable
Exposure times extended in
absence of stressor in ambient
environment
Dose reconstruction
Correlate ambient, external
concentrations with exposure

Rationale
Tissue concentrations can help to reveal the locations, distributions, frequencies, or
durations of stressor presence in the ambient environment.
Guide actions to prevent or control the source or origin of the stressors, thereby
reducing the potential for exposure.
Tissue levels of chemical stressors used to measure ambient concentrations after
cleanup actions or remediation, or after implementing new control measures at
sewage treatment facilities.
Tissue levels of chemical stressors used as surrogate measures of ambient
concentrations of APls in water.
Extreme spatiotemporal fluctuations in water concentrations of APIs obscure or
complicate evaluation of actual exposure. This is especially true for APIs that are:
(i) released episodically (event-driven. such as by the sporadic practice of disposal
or events causing large changes in usage rates or in the types of medication being
used), (ii) discharged by diurnal patterns in flushing, (iii) influenced by
seasonality. Tissue levels may serve to integrate exposure over time.
Uptake and bioconcentration of chemical stressors at concentrations below
no-effect levels in water can eventually achieve body-burden levels that exceed
effects levels.
When stressors can be bioconcentrated, exposed organisms serve as sentinels for
sources of pollution or ambient levels that might otherwise be too small to
directly detect.
Biomagnified residues extend the time during which exposure can occur, even after
the API is no longer present in the external environment.
Levels of exposure can be used to reconstruct the original dose.
If actual exposure can be calibrated to external exposure levels, then simple
chemical monitoring in water could possibly be used instead of more resourceintensive tissue monitoring for predicting exposure.

Deconvolute contributions to
biological effects originating from
natural (ambient) background

Natural incidence can playa role in certain biological conditions that also result
from exposure to stressors. Natural background can be confused with effect.
Understanding exposure helps to distinguish the two causes (e.g., Grim et al.

Detecting newly emerging stressors

Identifying previously unknown chemicals concentrated in tissues can reveal newly
emerging pollutants before any linkage with effects might be suspected; this is
particularly germane to new drug entities recently introduced to commerce.

2007).

Remarkably, given the voluminous literature on APls in the aquatic environment, little data exist
relevant to the occurrence of APIs as residues in the tissues of aquatic organisms. These limited data
come primarily from controlled studies using APls postulated or known to occur in the environment. These studies involve exposure experiments under controlled conditions (including fish caged
in the wild) and especially from studies of veterinary drug residues in aquacultured fish. Another
source of data exists in the form of calculated BCFs from predictive models. One of the ramifications of this is that except for the expected residues of certain veterinary APIs used in aquaculture,
it is essentially unknown what levels of the numerous APIs occurring in the ambient environment
might lead to human exposure via consumption of fish or other aquatic life. No human exposure
studies have been done on API residues in wild fish. It is known, however, that tissue residues of
certain APIs in aquacultured fish can resist degradation during cooking and can migrate from one
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tissue to another during cooking, as shown for the antibiotics oxolinic acid (OA) and flumequine
(Steffenak et al. 1994).

8.2.2

SOURCES/ORIGINS LEADING TO EXPOSURE

Thousands of distinct chemicals are formulated into tens of thousands of commercial products used
worldwide in the practice of human and veterinary medicine or for personal care. Those of most
interest in the aquatic environment include the APls that: (i) are most frequently used or used in the
greatest quantities (e.g., NSAIDs: nonsteroidal anti-inflammatory drugs) or which are commonly disposed by flushing into sewers, (ii) are the most potent (e.g., synthetic hormones such as EE2) or that
have clear potential for environmental effects (such as antibiotics, serotonin regulators, or oncolytics),
(iii) are excreted largely unchanged, (iv) share like-modes or mechanisms of action and which could
therefore act by concentration addition (e.g., SSRI antidepressants), and (v) can bioconcentrate.
The occurrence and disposition of APls in the environment is best viewed in terms of their
origins or sources, which comprise the locations from which they enter the environment and the
pathways by which they enter (and are initially distributed within) the environment. These are many
and varied, and even a simplified network flowchart can seem complex (see Figure 1 in Daughton
2008). The major sources that have the potential for impacting the aquatic environment are summarized in Table 8.2; an overview of the many sources and origins of APls in the environment is

TABLE 8.2

Sources/Origins of APls Significant to Aquatic Exposure
API Source/Origin

Human and veterinary
medications

Dual-use

Chemical categories

DBPs and transformation
pmducts
Manufacturing

Excretion

Description/Explanation of API Source

Human medications (over-the-counter; prescription only or legend drugs) include thousands
of distinct APIs comprising numerous categories used in diagnostics, prophylaxis (including
vaccines), cosmetics, lifestyle, and therapy. Veterinary medications (including those used in
aquaculture) primarily comprise anabolic steroids, parasiticides, and antibiotics, though other
medicines are also used for companion animals (e.g., fluoxetine).
Some APIs also have uses outside the practice of medicine. Some have dual use as pesticides
(e.g., lindane, pyrethrins, avermectins, azole fungicides, and warfarin); another example is
malachite green, a chemical used illegally in aquaculture but where aquatic exposure has
been documented as a result of other uses (Schuetze et a!. 2008). Some veterinary medicines
have even been evaluated for nonaquaculture pesticidal use directly in the aquatic
environment; for example, the sedative medetomidine has been proven effective as an
antifouling agent against barnacles (Hilvarsson et a!. 2007).
Lower and higher Mw synthetics; biologics (derived from organisms; e.g., antibodies,
vaccines, and interleukins); natural products; nanomedicines; halogenated APTs are common
(especially those containing fluorine).
Little is known regarding the halogenated disinfection by-products (DBPs) that might be
created from any number of APTs (e.g., Flores and Hill 2008); many metabolites or
environmental transformation products can be bioactive.
Release in effluent from pretreated and untreated APT manufacturing; perhaps a minor,
localized source in the United States, but possibly of greater significance in less developed
countries (e.g., Larsson et a!. 2007; Fick et a!. 20(9).
Pharmacokinetics for humans differ radically among APls, resulting in wide spans in
excretion efficiency of unmetabolized parent APls or in excretion of biologically active
metabolites; conjugates can act as reservoirs of parent APls once hydrolyzed during sewage
treatment or in the environment. Excretion apportioned between the feces and urine varies
among APls. Maternal-fetal transport of APTs in fish is not understood.
continued
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TABLE 8.2 (continued)
Sources/Origins of APls Significant to Aquatic Exposure
API Source/Origin

Description/Explanation of API Source

Bathing

Bathing and swimming release APIs directly to sewers or surface waters by two mechanisms,
both involving dissolution of APIs: (i) from medications applied directly to the skin, and
(ii) after excretion to the skin via sweat (Daughton and Ruhoy 2009),

Sewerage

Only the contributions from distributed sewer systems can directly impact the aquatic
environment; septic and advanced on site systems generally do not serve as direct sources, but
can be important in extreme conditions (e.g., improperly installed leach fields, direct
discharge from advanced onsite systems). Straightpiping of untreated sewage continues to be
practiced in some locales. Wet-weather events can cause discharge of untreated sewage.

Treated sewage effluent

The removal efficiency of APls from the influents to WWTPs varies greatly-from 0 to
essentially 100%, as a function of the properties of the individual API and the type of
treatment being used. Removal includes "destruction" (alteration of chemical structure) as
well as physical sequestration, such as by filtration or sorption to sludge (and subsequent
creation of "biosolids").

Biosolids, manure, pet
excrement

One disposal option for biosolids (treated sewage sludges), which can contain sorbed or
occluded APls, is amendment of agricultural soils; wet-weather runoff holds the potential for
transporting these APls to surface water via runoff; manure from farm animals and
excrement from medicated pets can also serve as a source (via wet-weather runoff).

Runoff

Primarily relevant to veterinary drugs from CAFOs (e.g., wet-weather flooding of retention
ponds) or leaching of manure or feces from domestic animals and pets; can also involve
human medications, which are experiencing growing usage with pets.

Wet-weather overflows
and straightpiping

Flows that exceed the capacity of sewage treatment plants and rural areas where sewers still
discharge directly to surface waters represent worst-case sources (e.g., combined sewer
overflows), as the concentrations of APIs in these waste streams would not be reduced by
treatment.

Locations where unused
medications accumulate

Leftover drugs tend to accumulate (and eventually require disposal from) a wide expanse of
locations, extending far beyond the domestic medicine cabinet (Ruhoy and Daughton 2008).

Disposal to sewerage

Unwanted medications are often disposed by flushing down sewer drains; this can involve
leftover, unused medications and also the residuals contained in used containers or delivery
devices (Ruhoy and Daughton 2(08).

Disposal to domestic
trash

Instead of disposal to sewerage, leftover medications are also disposed to domestic trash (this
is currently the preferred method recommended by the U.S. federal government, when
alternative collection options are not available) (U.S. FDA 2010; ONDCP 2009 [updated
October]). The leachate collected from trash disposed in engineered landfills is sometimes
returned to sewage treatment facilities, possibly serving only as a minor and indirect route to
the aquatic environment.

Commercial use

Agriculture (antibiotics) and aquaculture (medicated feeds) serve as sources in localized
environments; these sources can involve significant quantities of APIs, especially uneaten
medicated feeds (Rigos et al. 2(04).

Vaporization!
aerosolization

The vapor pressure (volatility) for the vast preponderance of APls is insufficient to serve as a
source (or route of loss) for the aquatic environment: vaporization might, however, serve as a
source for certain PCPs, such as synthetic musks (Aschmann et al. 200 I; Peck and
Hornbuckle 2004, 2006) and cyclic methylsiloxanes (Xu and Chandra 1999); indeed,
Galaxolide has been detected in the blubber from Antarctic fur seal (Arctocephalus gazelia)
from the South Shetland Islands (Corsolini 2009). APls can also get entrained on particulates
that can then become airborne (Ham scher et al. 2003; Cecinato and Balducci 2(07).

Note:

An overview of sources and origins of APls in the environment is also provided by Daughton (2007, 2008).
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provided by Daughton (2007, 2008). Sources and origins are important to understand not just for
exposure. A comprehensive inventory of sources and their individual significance relative to each
other with respect to contributions to environmental loadings can facilitate the prioritization of
actions needed to reduce, minimize, or eliminate the potential for exposure via source reduction or
pollution prevention. A complex array of processes acts upon APIs released into sewage to diminish
their ultimate concentrations in the aquatic environment. One example situation using the fluoroquinolones is provided by Golet et al. (2002).

8.2.3

EXPOSURE VARIABLES

A vast and complex array of variables and their interactions (involving both the stressor and the
target organism) dictate how and to what degree exposure occurs. These include the routes and
processes by which exposure occurs. Few of these variables are unique to aquatic exposure involving APTs, and all can play roles, either in concert or in sequence. Not all of the variables, however,
have been examined with respect to APIs. Many are relevant to controlled exposure studies and
therefore only have hypothetical applicability to exposure in the wild. Table 8.3 summarizes some
of the many aspects relevant to aquatic exposure and provides examples from the literature. Some
of these factors are incorporated in the conceptualized diagram of the "4Ts": toxicant, totality, tolerance, and trajectory (Daughton 2005). It is also important to recognize that just because a chemical stressor might not be detectable in any tissue does not mean that exposure has not occurred.
It could be that the analytical methodology cannot detect the stressor at a sufficiently low level
(the MDL is too high). After all, some concentration levels known to have effects are extraordinarily low. For example, effects from EE2 have been documented at the sub-ppt level in surrounding water (i.e., 0.05 ng/L) (Larsen et a1. 2008); diclofenac is purported to have pro-inflammatory
effects at concentrations as low as 10- 14 M (-3 pg/L) (Schirmer and Schirmer 2008). Moreover, the
kinetics involved with the processes governing exposure might be sufficiently fast that uptake by
an organism results in immediate formation of irreversible products of exposure, such as adducts,
or in metabolic transformation to bioactive products. These products might merely be biomarkers
of exposure or they might alternatively be biomarkers of effect. Regardless, in these situations
monitoring for tissue residues of the parent API may well yield negative data, and therefore exposure can be overlooked or underestimated.
The internal dose is a function of the external concentration, chemical state of the API (e.g.,
ionization), uptake by and distribution within the organism, and bioavailability. Since the amount of
stressor that actually interacts with receptors of toxicological consequence cannot be easily determined, surrogate measures are usually used to estimate the actual biologically effective dose. An
added difficulty arises in translating "concentrations" associated with sediments and particulates
to freely available portions. Studies of uptake from sediments are not common, one example being
Higgins et a1. (2009), who report on the uptake by an oligochaete of triclocarban.

8.2.4

SOME GENERAL PERSPECTIVES AND BACKGROUND
REGARDING AQUATIC TISSUE LEVELS OF

APls

Surprisingly few studies have been published that examine the occurrence of APIs not just in fish
but in any aquatic animal or plant. Moreover, most of these data have been obtained for veterinary
APIs (primarily antibiotics and estrogenic/androgenic steroids), which are used in aquaculture at
levels hir exceeding those found in the ambient environment. Most aquatic biomonitoring studies
designed to emulate exposure under ambient environmental conditions are performed under controlled conditions, often with exposure concentrations still exceeding those that would be found in
the ambient environment. Controlled exposure studies often use exposure concentrations that are
one or more orders of magnitude higher than those that exist in the ambient environment, usually to
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TABLE 8.3
Variables Involved with Aquatic Exposure
Variable Affecting
Exposure

Exposure under
controlled
conditions
Route of exposure
(free in wild)
Type of organism

Environmental
location
Stressor physical
status
Stressor properties
Ambient
environment

Engineering controls

Fate

Organism status

Organism behavior
and niche
Timing of exposure

Magnitude of
exposure

Example

Baths (immersion in static, replacement, or flow-through systems, sometimes using whole effluent
from sewage treatment or water collected from native environments), oral (bolus), injection (IP),
feeding, caged in wild, whole-effluent toxicity testing.
Gill (brachial) transport, dermal absorption, oral/gut, olfactory (e.g., transport of nanoparticles via
olfactory neurons), lateral-line sensory organ (e.g., Chiu et al. 2008).
Teleost and cartilaginous fish, macroinvertebrates (invertebrates such as insects, crustaceans,
mollusks, and worms), periphyton (e.g., Aufwuchs), plants, amphibians, and reptiles, waterfowl,
and mammals (e.g., otters).
River, wetland, lake, reservoir, estuary, marine; benthic, pelagic, interfacial monomolecular
monolayer; proximity to effluent from treated effluent discharge or raw sewage.
Dissolved in water column, particulate-bound (including incorporation into feed), sediment-bound;
uptake from water can differ dramatically from dietary uptake.
Water solubility, Kow' pKa, log D, log K"pw, MW, molecular size or cross section, molecular
conformation and steric factors, environmental/metabolic half-life, chirality, vapor pressure.
pH, temperature (or season), salinity, total dissolved solids, natural organic matter (Galvez et al.
2(08), dissolved oxygen or hypoxia, solar irradiance (photolysis), nutrient levels and turbidity
(Gordon et al. 2(06), geographic locale, and dilution (e.g., effluent-dominated streams yield
maximum concentrations). Season can affect performance of sewage treatment (e.g., via
temperature) and irradiance (e.g., for photolysis or growth of autotrophs). Season and locale can
also affect the types of APIs present in sewage because different medications are used in different
seasons and in ditIerent locales.
End-of~pipe treatment can reduce concentrations of some but not all APls; it can also lead to the
formation of biologically active products and API-based DBPs; efficiency is a function of the types of
engineered treatments used by manufacturers and municipalities (e.g., Snyder et al. 2007). Types and
efficiencies of treatment can vary considerably from country to country (e.g., see Larsson et al. 2(07),
The interactions of the stressor with the ambient environment dictate its fate; key processes are
microbial degradation, photolysis, and sequestration via sorption to sediments. But even short
environmental half-lives do not preclude a continual presence of those stressors that are continually
introduced, such as via treated sewage; this has been termed "pseudopersistence" (Daughton 2002).
Food supply, nutrient levels, health, prior exposure history, growth state, lipid content, injuries,
disease, age, gender, condition index/factor, body length, over-expressionlinhibition of efflux
pumps, species/strain. For example, nutrient concentrations and stoichiometry influence lower
trophic-level responses to triclosan (Fulton et al. 20(9).
Behavior involving feeding (free-feeding, sessile, filter-feeding), niche, trophic level, swimming/
migratory behavior, and attraction/avoidance, and how these influence proximity to source
(e.g., sewage outfalls) and aggregation; aquatic, marine, estuarine.
Windows of vulnerability, developmental life stage/reproductive status (e.g., embryo, egg, larval,
hatchling, fry, juvenile, adult, spawning) (Van Aerie et al. 2002). Simultaneous vs. sequential
exposure when multiple stressors are involved.
Aqueous concentration is a major determinant of actual internal exposure dose for aquatic
organisms. For APls, concentration is partly dictated by the degree of dilution in waters receiving
treated or raw sewage effluent (with effluent-dominated streams and streams receiving raw sewage
representing worst cases); other determinants include popUlation served, sewage flow rate, and
treatment technology. High stressor concentrations in controlled laboratory studies are often not
relevant to real-world exposure. Newer exposure studies, however, are exploring lower and lower
concentrations; need to ensure that studies are relevant to the real world (Hinton et al. 20(5).
BCFs are often higher at lower concentrations. Lack of exposure or etl'ects at higher
concentrations cannot be used to rule out the importance of lower concentrations because of
multiphasic and nonmonotonic dose-response.
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TABLE 8.3 (continued)
Variables Involved with Aquatic Exposure
Variable Affecting
Exposure
Duration/variability/
frequency of
exposure
Multiple stressors

Exposure history
Pharmacokinetics

Pharmacological
bioavailability

Aquatic
bioavailability

Transformation
products
Resiliency/
vulnerability
Biological
modulators of
exposure

NOIe:

Example
Constant, pulsed, discrete, episodic, acute/chronic, life cycle, and multi generational.

Simultaneous versus sequential exposure to multiple stressors. Multistressor interaction etfects
(e.g., additive, potentiated, antagonistic, and synergistic) may follow concentration addition or
independent action models; competition for-or facilitation of-transport across membranes.
Prior or simultaneous exposure to other stressors-both chemical and physical (e.g., temperature,
salinity, stress from prey, etc.).
ADME: absorption, distribution, metabolism (e.g., phase I and II), excretion/elimination-all
affecting half-life and disposition within organism (including depuration); reactivity within
organism (e.g., formation of adducts vs. bioconcentration within lipid).
Residues that are bound versus those that are free (e.g., particulate-bound APIs may not transport
across gills); sequestration and/or bioconcentration of body residues, e.g., within lipids, binding
with melanins (Larsson 1993; Testorf et al. 2001; Aubry 2002; Roffey et al. 2007) and as other
adducts; disposition in blood/plasma (primarily bound to proteins), muscle, bile, liver, brain,
gonads, eggs, skin, bone, etc.; these factors also have direct relevance to subsequent human
exposure to APls via the food chain (function of edible tissue distribution).
pH influence on ionization state and lipophilicity of APIs. Influence of sorption to suspended
particulate matter. Concentration enrichment within sediments. For example, higher Ko values
were observed for ciprofloxacin with fine particulate organic matter (FPOM) than coarse
particulate organic matter, resulting in a higher magnitude of exposure to benthic
macroinvertebrates consuming FPOM (e.g., collector-gatherers) (Belden et al. 2007).
Metabolites and environmental transformation products (e.g., degradates from photolysis or
halogenation during disinfection) may prove more important that the parent API.
Biochemical, physiological, and behavioral repertoire of an organism that determines its ability to
avoid exposure or reduce its magnitude or duration; ability to maintain internal homeostasis and
adapt to stressors (Clubbs and Brooks 2007).
Various biological processes can enhance, facilitate, or reduce exposure. Those that are
evolutionarily conserved play key roles. Among the most important considerations include
variations of API metabolism among aquatic organisms. Exposure defenses include p-GP efflux
pumps, which can also be induced/repressed by other stressors, especially APIs (see: Tan 2007);
cellular stress response (e.g., induction of heat shock proteins); facilitation might occur via active
transport (e.g., for APIs of low 1\,," or high MW).

Some of these factors are discussed in detail by Geyer et al. (2000) and van der Oost (2003).

maximize the chances of detecting and quantifying any amount that might accumulate. Most of the
aquatic studies involving human APIs have been published only in the last few years.
Some studies examine the presence of APIs (primarily estrogens) indirectly, by way of activity
assays. For example, Houtman et al. (2004) examined fish bile for estrogenic activity; but fractionation of the sample is required for assigning activity to a particular API. It is also important to note
that in many studies, especially those examining bile, the APIs can be present as metabolically
reversible conjugates, which mayor may not have been cleaved prior to analysis; so the API is not
really present in its parent form, although it can be reabsorbed once the conjugate is excreted into
the intestine, The interpretation of tissue levels of many APIs, especially the steroids, is greatly
complicated by the relative portions that are free versus conjugated.
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The analysis of bile for free and especially conjugated APIs has been well-established for over 30
years. In a summary of data acquired in the 1970s for over a dozen APIs, concentration in the bile
of the dogfish shark was already known (Guarino and Lech 1986). Concentrations in the bile versus
plasma were known to range up to factors of hundreds (e.g., warfarin and diethylstilbestrol) or thousands (e.g., methotrexate). The utility of bile in exposure monitoring is discussed by Adolfsson-Erici
(2005) and Pettersson (2006).
Almost no tissue-monitoring study has examined the optical isomer ratios of racemic APIs;
indeed, even the aquatic toxicity of chiral APIs has been little studied, with Stanley et al. (2006) publishing one of the first studies (with propranolol). Stanley et al. (2007) further examined enantiomerspecific sublethal effects of the antidepressant f1uoxetine on traditional endpoints (survival and
growth) and the ecologically relevant behavioral response of feeding behavior. Both studies by
Stanley et al. (2006, 2007) indicated that the more pharmacologically active enantiomer was more
toxic to fish when sublethal rather than lethal responses were examined. Clearly enantiomer-specific
bioaccumulation and effects of chiral compounds require additional attention and may necessitate a
priori considerations in ecological risk assessments (Stanley and Brooks 2009).
Although the significance of bioconcentration is largely one of establishing potential internal
dose, it is important to note that internal exposure is not necessary for an effect to occur. Certain
effects can occur when the target organ is external. This is the case, for example, with exposure of the
lateral-line sensory organ (e.g., Chiu et al. 2008) and for olfactory and taste exposure. Theoretically,
antibiotics could alter the natural community structure of microorganisms that reside on the external surfaces of any aquatic organism.
An important perspective regarding the range of APls and metabolites that have been and will
continue to be detected in aquatic tissues is that of "self-biasing detectability." Those APls with the
highest probability of being detected are those that (i) can be taken up from water or food, (ii) are
present in the highest concentrations, (iii) have the lowest MDLs, and (iv) have available appropriate
analytical reference standards. Regarding the second point, those present in the highest concentrations tend to be those with the higher required doses, and which therefore have lower potency (the
human acceptable daily intakes [ADIs] for residues of veterinary APIs in food therefore tend to also
be higher). The third point is rarely pointed out. MDLs among APIs in a particular tissue can vary
by more than 2 orders of magnitude. This means that APIs commonly present in tissues but having
high MDLs might not be detected. As an example, Ramirez (2007) targeted 25 APIs/metabolites
in fish in effluent-dominated streams and rivers. Of the seven that were detected, three had the lowest MDLs. Of the seven APTs with the highest MDLs, only one (gemfibrozil) was detected. Tissue
concentrations below 0.1-1 f,lg/kg are rarely reported because this usually falls below the current
method detection capability, primarily because of matrix interferences. But APIs could nonetheless be present at these levels and will therefore be overlooked or self-censored. In the case of API
metabolites, very few deuterated standard compounds are commercially available, which presumably has precluded their analyses in tissues compared with parent drugs.

8.2.5

PREDICTIVE MODELING

Empirical data for the uptake and bioconcentration of APTs by aquatic organisms is very limited. Such
data are primarily focused on the legacy POPs. The empirical data that do exist are fraught with quality
issues and uncertainty; extrapolations across chemical classes or aquatic species are notoriously unreliable. Acquiring empirical data is met with a number of hurdles, not the least of which are cost and animal welfare concerns. Data from real-world field conditions are even more limited than data obtained
under controlled laboratory conditions, and these data are poorly covered in the available electronic
databases. The bioaccumulation databases for fish have been summarized by Weisbrod et ai. (2007);
in vitro methods for measuring bioavailability in fish have been reviewed by Weisbrod et ai. (2009).
A comprehensive review of the literature on uptake and bioconcentration of organic chemicals by
aquatic organisms revealed thousands of BCFs and bioaccumulation factors (BAFs ) for 842 organic

301

Active Pharmaceutical Ingredients and Aquatic Organisms

chemicals in 219 aquatic species (Arnot and Gobas 2006). But nearly half of the BCFs had major
sources of uncertainty, and predicted values that usually underestimated empirical values, which
were sparse. BAFs under ambient field conditions were generally higher than BCFs obtained under
controlled conditions. None of these data, however, included APIs.
Ankley et al. (2005) point out that routine aquatic bioconcentration testing is not common, as
conventional APIs tend to be water soluble, with Kow values below 3. Even then, higher molecular
weights (MWs) or a propensity for facile transformation (e.g., via hydrolysis) often preclude bioconcentration. On the other hand, given the fact that APIs often rely on active transport for uptake (e.g.,
Van Bambeke et al. 2000), even low Ko" values sometimes may not preclude bioconcentration. A
significant aspect of APIs to note is that they are designed to minimize accumulation in the body
during intended use, so any build-up that might occur in aquatic tissue could prove toxicologically significant. Another factor that sets APIs apart from conventional POPs is their metabolismsometimes yielding products that themselves can bioconcentrate. This creates the need to calculate
"pseudo" BCFs-the ratio of tissue concentration of a metabolite and the aqueous concentration of
the parent API (such as for norfluoxetine).
Van der Oost et al. (2003) also stress that predicting bioaccumulation in fish using simple models
(e.g., relying on ~w) is "virtually impossible" and extremely prone to error even with sophisticated models. The dynamics imposed on APIs by pharmacokinetics in particular make prediction
extremely difficult to model.
In the absence of empirical data, computed BCFs (e.g., using Quantitative Structure Activity
Relationship-QSAR-calculations) are often relied upon-at least to try and inform which APIs
might be of concern with regard to bioconcentration. But this approach has major unknowns with
respect to pharmaceuticals (Walkeret al. 2004a, 2004b). Other approaches for prioritizing which APIs
might be of highest exposure concern include those that rely on informatics (e.g., Gunnarsson et al.
2008, Kostich and Lazorchak 2008) or water/sediment monitoring (e.g., Lissemore et al. 2006).
Cunningham et al. (2009) reported on calculated BCFs in fish for 43 APIs. They range up to
highs of 353 Llkg (atovaquone), 190 (dutasteride), 64 (beclomethasone), and 51 (nabumetone), but
nearly all of the remainder were less than 4 Llkg. In a major analysis of the factors involved with
bioconcentration, Geyer et al. (2000) provide calculated Kow values or BCFs for a number of natural
and synthetic estrogens and estrogenic chemicals, androgenic steroids, and nonsteroidal antiandrogenic chemicals. Quite a number of computed BCFs are mentioned by Grung et al. (2007), and a
number of computed BCFs for lipid-regulators are provided by Hernando et al. (2007). Other predictive modeling approaches are explored in Section 8.4.
The many variables and pitfalls in determining BCFs and their use for predicting BAFs are
discussed by Parkerton et al. (2008). These issues, which surround the soundness or quality of
BCF/BAF data, were not evaluated in the summary of published data reported in this chapter.

8.2.6

OVERVIEW OF FISH TISSUE AND OTHER RESIDUE DATA FOR

APls

The study of the exposure of fish to APIs is dominated by endocrine-disrupting compounds [EDCs;
predominately by the natural and synthetic estrogenic sex steroids-primarily I7,B-estradiol (E2)
and EE2; comparatively less focus is directed at androgens] and by antibiotics and biocides (such
as triclosan). Comparatively few data exist for other drug classes. Most studies regarding EDCs
obviously concern reproductive and other direct endocrine effects. Little exists on exposure to APIs
having the potential to lead to subtle, difficult-to-detect effects such as alteration of behavior or
perturbations of the immune system (e.g., Hoeger et al. 2005, Salo et al. 2007).
Exposure studies regarding endocrine disruption have been dominated by the numerous studies demonstrating that fish are impacted by exposures to treated and untreated sewage. The first of
these. which linked exposure to sewage with estrogenicity, was published in 1994 (Purdom et al.
1994). Most evidence for exposure is inferential. Few studies have established the possibility of
exposure to either individual or combinations of specific API EDCs.
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Excluding the data collected on fish uptake of antibiotics as a direct or indirect result of usage in
aquaculture, actual empirical data are rare for fish-tissue residues of APIs resulting from exposures
in the environment or exposures under controlled conditions emulating ambient concentrations.
Determination of empirical BCFs is rarer yet. These data come from two major categories: (1) fish
collected from (or caged in) wild, native environments and (2) fish exposed under controlled conditions in the laboratory. Collectively, these data exist only for about 30 different APIs, some of which
were the subject for just a single study (Ramirez et al. 2007).
The limited data on residue levels from exposure in the natural environment are extremely limited, primarily comprising: SSRIs (especially paroxetine, fiuoxetine, sertraline, and some principal
metabolites such as norfiuoxetine and norsertraline), NSAIDs (diclofenac, naproxen, ketoprofen,
and ibuprofen), steroids (estrone [EI], E2, and EE2), and diphenhydramine, diltiazem, gemfibrozil,
and carbamazepine (CBZ). Also available are data for biocides (triclosan, methyl triclosan, and
triclocarban) and malachite green and its leuco metabolite.
Tissue residue levels resulting from exposures under controlled conditions are a bit more
common, including many of the same ones as detected under environmental monitoring, but also
including: ,B-blockers (propranolol and atenolol), fungicides (the triazoles: bromuconazole, cyproconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole,
and triadimefon), the macrocyclic lactone avermectin Bl, steroids (hydroxyestrone, estriol [E3],
17,B-dihydroequilenin, and testosterone), and mono- and di-brominated derivatives of EE2.
These data are discussed in more detail in the succeeding sections. While on the one hand it is
interesting that most of these APIs have BCFs greater than unity (considering their generally low
Kow values), few have BCFs above 1000 and therefore do not have anywhere near the accumulation potential of the POPs. The tissue levels of low-Kow APIs point to uptake mechanisms beyond
passive diffusion. The greatest concentrations tend to be in the bile and liver. Actual bioconcentration of diclofenac seems to be higher than for most APIs. The computed BCF for fiuvastatin
is among one of the highest for any API. But the highest measured BCFs are for the biocide
triclosan, which was found to range upward of 10,000 in the intestines of zebra fish (Orvos et al.
2002). The most empirical data exist for steroids and antibiotics. While residues in edible tissues have clear ramifications for human exposure, residues in organs such as the brain (a focus
for monitoring targeted at SSRIs) have implications regarding immediate biological effects. All
residues have implications with respect to trophic biomagnification, which has not been studied
with respect to APIs.
8.2.6.1

SSRls/SNRls (Selective Serotonin and Serotonin-Norepinephrine
Reuptake Inhibitors)

Fluoxetine and sertraline and their principal metabolites (norfiuoxetine and norsertraline) were
detected in all fish tissues (brain, liver, and muscle) from three fish species collected from Pecan
Creek TX, an effluent-dominated stream: Lepomis macrochirus (bluegill), Ictalurus punctatus
(channel catfish), and Pomoxis nigromaculatus (black crappie) (Brooks et al. 2005). All four
analytes were detected in all tissues at levels exceeding 0.1 ng/g; no residues were detected in
fish from a reference site not receiving effluent discharges. Compared with average tissue levels
of fiuoxetine and sertraline, the average levels for norfiuoxetine and norsertraline were higher
in brain, liver, and muscle. The highest concentrations for each API were detected in the brain,
generally followed by the liver: norsertraline (15.6 and 12.94 ng/g), norfiuoxetine (8.86 and 10.27
ng/g), sertraline (4.27 and 3.59 ng/g), and fiuoxetine (1.58 and 1.34 ng/g); the lowest concentrations were in muscle: norfiuoxetine (1.07 ng/g), norsertraline (0.69 ng/g), sertraline (0.34 ng/g),
and fiuoxetine (0.11 ng/g). These levels are roughly 0-4 orders of magnitude higher than reported
in wastewater and effluent-dominated streams, refiecting bioconcentration as well as the possibility of active transport. Although hypothetical human dietary exposure from these fish would
yield daily intakes roughly 6 orders of magnitude below therapeutic doses, note that ADIs exist
only for veterinary drugs.
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Schultz et a1. (2010) recently reported extensive data from a monitoring study involving the
largest suite of APIs yet targeted from any single therapeutic class (SSRIs/SNRIs); they also collected concomitant data from three matrices (water, bed sediment, and brain tissue of white sucker,
Catostomus commersoni) from two effluent-impacted streams in Iowa and Colorado. They targeted
JO antidepressants (including two metabolic/transformation products): bupropion, citalopram,
duloxetine, fluoxetine (and norfluoxetine), fluvoxamine, paroxetine, sertraline (and norsertraline),
and venlafaxine, an SNRI. All but two (duloxetine and fluvoxamine) were found in brain tissue.
Of particular interest was the distinct lack of correlation between the types and quantities of these
APls measured in the stream waters versus those in the brain tissues. Venlafaxine was found in
most of the stream samples at concentrations consistently higher than the next two most prevalent
(bupropion and citalopram), sometimes at levels over an order of magnitude higher. The levels
of venlafaxine in the streams sometimes exceeded 0.5 Ilg/L. In contrast, the primary analytes in
brain tissue were norsertraline and sertraline, followed by norfluoxetine and fluoxetine. Indeed little
venlafaxine, bupropion, or citalopram were found in brain tissue but were prevalent in sediments
(although their relative levels were generally the inverse of those in brain tissue). These data point to
the possible involvement of selective uptake of these chemicals into brain tissue. The maximum and
the range of mean concentrations (ng/g) in brain tissue were: norsertraline (28.9; 0.01-3), sertraline
(4.24; 0.005-1.8), norfluoxetine (3.57; 0.07-0.9), and fluoxetine (1.65; 0.02-0.6). The maximum
level reported for norsertraline (28.9 ng/g) is the highest yet reported for an API in brain tissue.
In a more recent study, Brooks et al. (in preparation) observed sertraline, norsertraline, flu oxetine, and norfluoxetine at low ng/g levels in periphyton and three taxa of benthic macroinvertebrates (Corbiculajluminea, Argia sp., hydropsychidae) collected from Pecan Creek TX, indicating
that dietary exposure to fish from these SSRls and potentially other APTs deserve further study. As
noted elsewhere in this document, extraction and analysis approaches to account for matrix differences among aquatic organisms require further development. For example, a recent study advanced
extraction techniques for identification of APTs in mollusks (Cueva-Mestanza et a1. 2008).
Fish from a Lake Ontario harbor receiving sewage effluent were analyzed for SSRIs by Chu and
Metcalfe (2007). Seven fish were collected from three species [three brownbullhead (Ameiurus
nebu/osus), three gizzard shad (Dorosoma cepedianum), and one white perch (Morone americana)1 and analyzed for paroxetine, fluoxetine, and norfluoxetine. Concentrations on the basis of
whole wet weight ranged up to 1 Ilg/kg: paroxetine (0.48-0.58 Ilg/kg; 3 of 7 samples), fluoxetine
(0.14-1.02 Ilg/kg; 6 of 7 samples), and norfluoxetine (0.15-1.08 Ilg/kg; 4 of 7 samples); neither
fluoxetine nor norfluoxetine was detected in white perch. This occurrence of paroxetine is the first
reported in the literature.
In a 2-year study in the Caloosahatchee River, Florida, water samples and the plasma of juvenile bull sharks (Carcharhinus leucas) were analyzed for four SSRIs and a metabolite (citalopram,
fluoxetine/norfluoxetine, paroxetine, and sertraline) and an SNRI (venlafaxine) (Gelsleichter 2009).
Only citalopram, sertraJine, and venlafaxine were detected in wastewater or river-water samples.
All analytes except for fluoxetine, however, could be detected at very low quantifiable levels in at
least one plasma sample from at least one of the 2 years. Sertraline was the only analyte detected in
all samples in 2006, while only venlafaxine and citalopram were detectable in 2007.
The bioconcentration of fluoxetine at an exposure concentration of 10 Ilg/L by Japanese medaka
(Oryzias lalipes) was evaluated under controlled conditions, at three pH values below the pKa
(Nakamura et al. 2008). The empirical BCFs were 8.8, 30, and 260 for the body and 330, 580,
and 3100 for the liver, at respective pH values of 7, 8, and 9; the BCF for fluoxetine summed
over the body and liver was 11 at pH 7.2. The BCFs increased with increasing pH since fluoxetine
is a weak base and uptake of the nonionized molecule is facilitated by diffusion. Not unexpectedly, the N-demethylated metabolite norfluoxetine was similarly recovered. BCFs predicted from
liposome/water equilibration did not increase as much with increasing pH as did BCFs predicted
by octanollwater partitioning (with control of ionic strength). Bioconcentration of an API such as
fluoxetine, while made complicated by pH influencing ionization, differs dramatically from the
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bioconcentration of a conventional, long-lived POP. It is further complicated when the API (such as
f1uoxetine) can be metabolized to another chemical species (in this case, norfluoxetine) that is also
subject to bioconcentration. Since S-norfluoxetine binds to the serotonin reuptake transporter with
affinity similar to that of R-f1uoxetine and S-f1uoxetine (Wong et al. 1993), the combined sum of the
parent compound and active metabolite should be considered in determining bioconcentration and
effects in ecological risk assessment.
Using caged fathead minnows in the outfall from sewage treatment plants, Metcalfe et al. (2010)
detected venlafaxine, citalopram, sertraline, and a demethylated metabolite from each (as well as
norfluoxetine) at levels roughly ranging from 1 to 4 ng/g (whole-body wet weight). Only sertraline,
however, was detected in more than one of the three sites examined.
Research on the pharmacokinetics of APIs in fish is very sparse. Schultz et al. (2001) published
perhaps the first study-on 17a-ethinylestradiol. Paterson and Metcalfe (2008) published an initial
examination of the uptake and elimination of f1uoxetine. At the outset of exposure to 0.55 f./g/L in
water over 7 days, accumulation by medaka was noted within the first 5 h; norfluoxetine was also
noted at this time at about 40% of the f1uoxetine level. A peak tissue concentration of 49 f./g/kg was
recorded after 3 days for f1uoxetine. After 6 days, norfluoxetine exceeded f1uoxetine: 64 f./g/kg versus 40 f./g/kg. This yielded a BCF of 74 for f1uoxetine and a pseudo-BCF of 117 for norfluoxetine.
These studies (Brooks et al. 2005, Chu and Metcalfe 2007, Nakamura et al. 2008, Paterson and
Metcalfe 2008, Schultz et al. 2010) collectively show that an API metabolite (such as norfluoxetine)
can accumulate to equal or greater tissue concentrations than its parent (e.g., f1uoxetine), which is
not surprising since norfluoxetine is more nonpolar than f1uoxetine. This is important when the
metabolite (such as norfluoxetine) is bioactive. Metabolic conversion of the parent API means that
its measured BCF will be lower than its actual BCF. Presence of an API in tissue might serve as an
indicator of higher exposure to a metabolite of similar or higher biological activity. Whether these
residues are bioavailable, however, is a key question, as shown by Zhou et al. (2008) who reported
that the BCFs for "free" (unbound and directly bioavailable) f1uoxetine were less than unity, while
those for total f1uoxetine were in the range reported by these previous studies. It is also not always
clear whether API metabolites in tissues result from endogenous metabolism or from uptake of preexisting metabolites from water.
Clearly, the relationship between coexposure to SSRIs/SNRIs, tissue residues, and potential biological effects requires further study. This was highlighted by the recent work of Painter et al.
(2009), which identified environmentally relevant concentrations of a mixture of SSRIs/SNRIs to
adversely affect fathead minnow predator escape behavior.
8.2.6.2

NSAIDs (Nonsteroidal Anti-inflammatory Drugs)

Given the widespread usage of NSAIDs and the published data on their environmental occurrence and ecotoxicology, surprisingly few studies have monitored for any of the NSAIDs in aquatic
organisms.
Brown et al. (2007) exposed caged juvenile rainbow trout to sewage effluent at three sites and
measured plasma levels for various NSAIDs (and gemfibrozil). This was the first reported measurement of fish plasma levels of diclofenac, naproxen, and ketoprofen (as well as gemfibrozil)
after exposure in the field. All except ketoprofen showed a propensity to bioconcentrate in plasma.
Plasma concentrations ranged from tens to several thousand ng/mL, with the highest being for
gemfibrozil. Of particular significance was the wide range of BCFs for any particular API across
the study sites. The wide variance in BCFs did not seem to be a function of API concentration in the
water, temperature, pH, or exposure time; the authors concluded that some other chemical characteristic of the effluents governed uptake, possibly the presence of colloids or surfactants. Compared
with predicted BCFs, all of the APIs, with the exception of ibuprofen, had BCFs that ranged from
unity to considerably lower.
Under static exposure to high nominal concentrations (490~1000 f./g/L), plasma levels ranged
from: 60 ng/mL (ketoprofen), 3440 (diclofenac), and 3640 (naproxen), to 4680 (ibuprofen); under the
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same conditions, the level for gemfibrozil was 21,500. These gave empirical BCFs ranging from: 0.1
(ketoprofen),4 (naproxen), 7 (diclofenac), to 9 (ibuprofen) [and 63 for gemfibrozil].
During the caged study, the exposure levels at the three sites ranged from 4.5 ng/L (ibuprofen)
to 2320 ng/L (diclofenac). Resulting plasma concentrations ranged from undetectable (ketoprofen),
12 ng/mL (diclofenac), 14 (naproxen), and 84 (ibuprofen) (and 210 for gemfibrozil). These gave
BCFs ranging from: <11 (ketoprofen), 5 (diclofenac), 56 (naproxen), to 18,667 (ibuprofen) (and 199
gemfibrozil).
With juvenile rainbow trout exposed under continuous flow for 96 h to 920 fJg/L ibuprofen, after
the first 24 h of exposure, the plasma concentrations of ibuprofen increased, beginning at about
7 fJg/mL and ending at about 10.6 fJg/mL (Huggett et al. 2004), in rough agreement with the data
from Brown et al. (2007).
The bioconcentration of diclofenac by fish was reported for the first time by Schwaiger et al.
(2004). Rainbow trout (Oncorhynchus mykiss) were exposed for 28 days to concentrations ranging
from I to 500 fJg/L. Concentrations in the liver were about 40-fold greater than in muscle. With
exposure to 1 fJg/L, tissue residue concentrations were about: 2882 ng/g (liver), 1025 ng/g (kidney), 805 ng/g (gills), and 73 ng/g (muscle), yielding BCFs (Llkg) of 2732 (liver), 971 (kidney),763
(gills), and 69 (muscle); plasma levels were not reported. Tissue concentrations increased linearly
with increasing dose, up to 500 fJg/L, which yielded tissue concentrations roughly twice those from
the l-fJg/L dose. The lower tissue concentrations with respect to dose are the reason the calculated
BCFs decreased with increasing concentrations.
Mehinto (2010) reported bile BCFs in the narrow range 509-657 after 21-day exposures of trout
to diclofenac at 0.5, 5.0, and 25 ng/L.

8.2.6.3 Lipid Regulators
Gemtibrozil was shown to bioconcentrate in the plasma of goldfish (Carassius auratus) after laboratory exposure to an environmentally relevant concentration of 0.34 fJg/L (nominal 1.5), as well as a
higher concentration of 852 fJg/L (nominal 1500) (Mimeault et al. 2005). After 14 days of exposure,
plasma BCFs were 500 and 92, respectively, resulting from respective plasma concentrations of
roughly 170 and 78,000 fJg/L. Uptake was concluded to occur across the gill membrane but passive
diffusion or active transport could not be distinguished.
In the same study with four NSAIDs, gemfibrozil was measured in the plasma from rainbow trout
caged in effluent-dominated streams and during a controlled static exposure experiment (Brown
et al. 2007). This was the first measurement of a fish plasma level of gemfibrozil after ambient exposure in the field. Of the five APls, the resulting plasma levels were highest for gemfibrozil. Static
exposure to a high level of 510 fJg/L gave a plasma level of 21,500 ng/mL, yielding a BCF of 63. In
the caged field study, the plasma level reached 210 ng/mL, yielding a BCF of 199.
A compendium of calculated Kow and BCF values for a number of fi brates and statins is provided
by Hernando et al. (2007). While the 10gKow values all indicate relatively high Iipophilicity (most
exceeding 4), computational approaches for estimating BCFs showed relatively low values (3.2)
for bezatibrate, gemfibrozil, clofibric acid, fenofibric acid, and pravastatin, and 56 for atorvastatin;
values ranged from 120 to 380 for clofibrate, fenotibrate, lovastatin, and mevastatin. Higher computed values were found only for simvastatin (800) and fluvastatin (2000). These values might be
useful for targeting these latter two statins for biomonitoring to determine actual empirical BCFs.
Note, however, that the low computed BCF for gemfibrozil is not predictive of the empirical BCFs,
being 1-2 orders of magnitude lower than those measured by Mimeault et al. (2005) and Brown
et al. (2007).
8.2.6.4 fl-Blockers
Owen et al. (2007; also unpublished data; Owen et al. 2009) exposed juvenile rainbow trout to relatively high levels of propranolol: 10 mg/L for 10 days. Plasma levels of about 5 fJg/mL were reached;
concentrations were often 40-80% of the water levels after 40 days.
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Winter et al. (2008) exposed fathead minnows to relatively high concentrations (0.1-10 mg/L)
of atenolol. Compared with water concentrations, plasma concentrations ranged between 1.8% and
6.2% (for males) and 0% and 12.2% (females). The male fish plasma concentration for atenolol
corresponding to the exposure concentration for the LOEC (Lowest observed effect concentration)
condition index (3.2 mg/L) was 0.0518 mg/L (51 Ilg/mL).
Cleuvers (2005) reported calculated BCFs of 4.47 and 0.89 for propranolol and metoprolol, and
a value for atenolol too low to calculate. But ,B-blockers were not detected in fish during a study by
Brooks et al. (2005, unpublished data).

8.2.6.5

Fungicides

Juvenile rainbow trout (0. mykiss) were exposed to nine triazole fungicides (dual-use pesticides
and pharmaceuticals) in feed containing each at 23-35 flg/g (wet weight) (Konwick et al. 2006).
These triazoles had log Kow's ranging from 2.9 to 3.9: bromuconazole, cyproconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, and triadimefon.
Each compound was taken up quickly, reaching steady state after a day of exposure. They quickly
reached concentrations in body lipids ranging from roughly 0.5-1 flg/g lipid, yielding biomagnification factors (on the basis of lipid content of fish vs. lipid content of food) ranging from 0.006
(propiconazole) to 0.012 (triadimefon and tebuconazole).

8.2.6.6

Macrocyclic Lactones

The macro-lactone dual-use parasiticides (used in veterinary medicine) are best known as the avermectins. Examples of these large, polycyclic lactones include: abamectin, albendazole, doramectin,
emamectin, eprinomectin, ivermectin, morantel, moxidectin, milbemycin, and selamectin. Residues
are well-established as occurring primarily in liver and lipid tissues, followed by kidney and muscle.
An overview of this chemical class is provided by Danaher et al. (2006). Escher et al. (2007) point
out that uptake kinetics and calculated BCFs are lower than predicted based on hydrophobicity. This
is hypothesized to result from membrane exclusion because of the large molecular cross section.
Avermectin BI (abamectin) was shown to resist uptake by sturgeon (into muscle) (Shen et al.
2005); biomagnification therefore would not occur. After a 22-day exposure to 0.2 and I ng/mL in
water, concentrations in muscle reached steady state in about 2 weeks, giving muscle concentrations
of 7.75 and 38.29 ng/g, respectively, yielding BCFs of 41-42.
Exposure for 28 days of bluegill sunfish (L. macrochirus) to an aqueous concentration of
0.099 flg/L avermectin Bla gave tissue concentrations of 6.8, 3.0, and II flg/kg, in whole fish,
fillet, and viscera, respectively, yielding BCFs of 56,28, and 84 (Van den Heuvel et al. 1996). As
with other studies, it was concluded that abamectin does not strongly bioconcentrate and would
therefore not be expected to biomagnify.

8.2.6.7

Steroids

Determining the uptake and bioconcentration of steroids is complicated by the fact that many of
them have multiple origins. Several of the estrogens, for example, are endogenous to all fish (and
some invertebrates but not plankton). Endogenous production can be further complicated by substances that induce synthesis (e.g., via aromatization) or inhibit excretion (e.g., repression of efflux
pumps). But they also have at least two other origins. The first is the subject of this chapter-many
have origins from the pharmaceutical preparations in which they are used; even ,B-estradiol is used
in certain hormone preparations. The second origin is from other fish, which excrete a variety of
steroids, for example as pheromones (Scott and Ellis 2007). These origins become intermingled
with that resulting from endogenous synthesis; for estrogens and androgens, this becomes problematic for modeling female and male fish, respectively.
The steroids are also intimately involved in a metabolic cascade that involves interconversion,
such as via aromatization, and conjugation. Uptake from surrounding media continually adds to
the pool involved with natural metabolic processes. These factors greatly complicate the modeling
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of uptake and bioconcentration. Given the dynamic state of uptake, interconversion, and excretion,
steady-state concentrations are probably rarely reached in laboratory studies; life-cycle studies are
rare. This leads to very wide ranges in both predicted and measured tissue concentrations and
BCFs-measured both under controlled laboratory conditions and in the wild. An overview of the
environmental occurrence and consequences of exposure of fish to natural and synthetic estrogenic
chemicals (of which only a small portion are APIs) is provided by Tyler et al. (200S); further discussion on bioaccumulation of E2 and EE2 is provided by Langston et al. (200S). A method using gas
chromatography/mass spectrometry was developed for simultaneously quantifying 12 endogenous
steroids in plasma and bile, using flounders (Platichthys fiesus) as the test species (Budzinski et al.
2006); the steroid analytes spanned the estrogen/androgen metabolic cascades from pregnenolone
and progesterone to E2 and ll-ketotestosterone.
One major but very limited source of data on uptake and tissue levels of estrogenic and androgenic
steroids is from the aquaculture literature. Steroids are used to induce sex reversal in farmed populations. These data are not covered here. The data of Stewart et al. (2001) serve as one example.
Rainbow trout (0. mykiss) and roach (Rutilus rutilus) exposed to treated sewage effluent in
controlled continuous-flow tanks concentrated El, E2, and EE2 in the bile-at levels beyond
endogenous production (Gibson et al. 200Sa, 200Sb). Most was present as glucuronide conjugates.
Bioconcentration was roughly 4000-6000 for EE2 and 10,000-13,000 for E2 and El combined. The
conjugated equine estrogen (CEE) metabolite, 17,B-dihydroequilenin (17,B-Eqn), was also detected;
while this is perhaps the first report of 17,B-Eqn in an aquatic organism (or in any environmental
sample), its specific source was unknown (e.g., whether an endogenous metabolic product vs. an
ingredient from a conjugated equine hormone preparation).
This work on CEEs (Gibson et al. 200Sa) was extended further in a comprehensive examination of treated and untreated sewage and fish exposed under controlled conditions (Tyler et al.
2009). Treated sewage from wastewater treatment plants (WWTPs) in the United Kingdom
were examined for six CEEs: equilin (Eq) and equilenin (Eqn), and four metabolites, 17,Bdihydroequilin (17,B-Eq), 17 a-dihydroequilin (17 a- Eq), 17,B-dihydroequilenin (17,B-Eqn), and
17a-dihydroequilenin (17a-Eqn). The bile from two species of fish (rainbow trout and the common carp, Cyprinus carpio) exposed to treated sewage effluent was also analyzed. Among these
six CEEs, only two (Eqn and its metabolite 17,B-Eqn) were detected in wastewaters. Eqn concentrations ranged from 1.32 to 2.S9 ng/L (influent) and 0.32-1.32 ng/L (effluent), and 17,B-Eqn
ranged from <0.2 (LOD) to 0.37 ng/L (influent) and 0.07-0.1S ng/L (effluent), concentrations on
par with those of E2 and EE2. The authors pointed out that since these two CEEs occurred in
sewage influent, their origin from hormone replacement products was more probable than from
exogenous metabolic processes. 17,B-Eqn (as in the prior study) and now Eqn (for the first time)
were the only two CEEs detected in bile. BCFs for trout exposed to 17,B-Eqn were calculated to
be 1.S x 10 6 and 2.2 x 10 6 for trout exposed to Eqn.
Notably, the study of Tyler et al. (2009) is one of the very few focusing on aquatic exposure to
also extend its findings to the potential for effects from exposure to environmentally realistic concentrations. Concentrations of 17,B-Eqn as low as 0.6 ng/L elicited a vitellogenic response in trout,
as well as all but the lowest exposure concentration of Eqn (4.2 ng/L); the carp were nearly three
orders of magnitude less sensitive. A 17,B-Eqn concentration of 0.6 ng/L nearly intersects with its
concentrations detected in the treated UK wastewaters, providing a rare linkage between real-world
exposure levels and the potential for adverse effects.
The difficulty in tying exposure to effects is demonstrated in another unique study, involving
fish showing signs of possible exposure to estrogens. Three separate projects involved male bream
(Abramis brama) with ovotestis and vitellogenin from two different locations in the Netherlands
and whitefish (Coregonus lavaretus) with malformed gonads from Lake Thun, Switzerland
(Vogeli 200S). In the ovotestis case, while levels of EI, E2, and EE2 in adipose tissue did not differ from controls, levels of EI and EE2 in bile showed bioaccumulation in the ovotestis fish; E2
did not differ from the control. In contrast, with the case of elevated vitellogenin, levels of El, E2,
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and EE2 were higher in the bile of the controls. With the group with malformed gonads, only El
and E2 were present (above the MDLs) in the bile of all fish but the levels were higher in the fish
with normal gonads.
In male Rainbow trout exposed to EE2 at relatively high nominal water levels of 125 ng/L, EE2
was shown to be rapidly absorbed (Skillman et al. 2006). EE2 was detected in plasma upon the first
sampling time of 15 min and reached a steady-state range of 60-90 ng/mL within 16 h, yielding a
BCF of up to 720. Levels in the liver corresponded with those in the plasma. In the bile, levels of
free EE2 were also similar to those of the plasma and liver. In the bile, however, conjugated EE2
continued to increase, until 99% of the total EE2 in the bile comprised conjugated glucuronides.
The authors conclude that EE2 in plasma, reaching equilibrium levels several hundred-fold higher
than in water, represents a viable means for measuring current environmental levels; bile levels,
in contrast, were more representative of cumulative exposure. The study also followed the parallel
time course synthesis of vitellogenin and gene expression.
A model developed by Lai et al. (2002b) predicted relative bioconcentration of steroids, ranging
from fish at the highest trophic level (1.8 for E3) to fish at the lowest trophic level (332 for EE2).
In another study (Lai et al. 2002a) examined the uptake of natural (El, E2, hydroxyestrone, and
E3) and synthetic (EE2 and estradiol valerate) estrogens by the freshwater alga, Chiarella vulgaris. Under static conditions, all the estrogens were taken up, but E3, hydroxyestrone, E2, and EE2
could not be detected, because of metabolism. No equilibria could be reached, except for El, for
which a BCF of about 27 was calculated. On the basis of Kow' EE2 would be expected to accumulate more, but did not-possibly because of active transport of the endogenous estrogens or active
efflux of EE2.
Juvenile rainbow trout (0. mykiss), under controlled conditions, were exposed to sewage under
continuous flow before and after treatment by sand filtration (Pettersson et al. 2006). After 28 days,
bile was sampled. When exposed to untreated water, levels of El were two orders of magnitude
higher than in controls (4.0 f./g/g vs. 0.04 f./g/g). Bile levels were also higher compared with controls
for EE2 (0.25 f./g/g vs. 0.10 f./g/g) and E2 (0.17 f./g/g vs. 0.04 f./g/g). When exposed to treated water
(posts and filtration), the bile concentrations for El (0.17 f./g/g) and E2 (0.04 f./g/g) were reduced
considerably. The concentration for EE2, however, was slightly higher (0.38 f./g/g).
In a subsequent study, Pettersson et al. (2007) examined the bile of perch (Perea fiuviatilis L.)
from the coastal waters of the Swedish Baltic Sea impacted by sewage for El, E2, and EE2. Studies
of fish from the wild are uncommon. EE2 was never detected, in contrast with El and E2, which
were almost always present. These levels did not differ significantly from samples obtained from
reference sites. These findings, however, corroborated lack of signs of endocrine effects, possibly
because of efficient sewage treatment practices.
In another study using fish in the native ambient environment, Vermeirssen et al. (2005) used
caged brown trout downstream of sewage effluents at five sampling sites. They measured E2, El,
and EE2 but did not report them separately-only as estradiol equivalents. Houtman et al. (2004)
also indirectly measured EE2 via estrogen assay (in the bile of male bream, A. brama).
In a study of juvenile bull sharks (c. leueas) in the Caloosahatchee River, Florida, EE2 was
detected in plasma at levels only up to slightly above the MDL (Gelsleichter 2009). EE2 was detected
only during the second of 2 years of sampling (2006-2007), being detected in 7 of the 12 sharks
sampled; EE2 was not detected in the Myakka River, a control river that did not receive treated
wastewater. Levels of EE2 in the river ranged only up to 0.23 ng/L. Of the seven shark plasma samples with detectable residues, the two that could be quantified ranged up to 3.79 ng/mL plasma.
Perhaps the first bioconcentration study of EE2 in fish was reported by Larsson et al. (1999).
Caged juvenile rainbow trout (0. mykiss) were exposed to an effluent-dominated stream, and El,
E2, and EE2 were measured in bile. The respective concentrations (conjugated and unconjugated
combined) for El, E2, and EE2 in the bile after 2 and 4 weeks were (approximately): 0.6 and 2.5
f./g/g; ND and 1.0 f./g/g; and 0.3 and l.l f./g/g. These bile concentrations of roughly 1 ppm were about
4-6 orders of magnitude higher than the water levels. A separate static study using juvenile rainbow
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trout exposed for 46 h to 5 iJg/L of either El, E2, or EE2 produced respective bile concentrations of
>400, -200, and -350 iJg/g.
Perhaps the first full life-cycle bioconcentration study of EE2 in fish was reported by Lange et al.
(2001). A life-cycle exposure study, using the fathead minnow (Pimephales promelas) was done
using newly fertilized embryos (24-h old) under continuous flow for 305 days at five concentrations
of EE2: 0.2, 1.0,4.0, 16, and 64 ng/L (Lange et al. 2001); note that the two highest concentrations
were toxic. No EE2 could be detected in tissue «0.38 ng/g) after exposure at 0.2 and 1.0 ng/L test
concentrations 192 days posthatch. At 16 ng/L (239 days posthatch) and 64 ng/L (153 days posthatch), the EE2 tissue levels were 7.3 and 31 ng/g, yielding BCFs of 610 and 660, respectively. The
authors concluded that the BCF (L/kg) was likely less than 500 (and probably less than 2400) for
healthy fish. A more recent study by Caldwell et al. (2008) provided an HC5 value (hazardous concentration predicted to negatively affect 5% of the population) of 0.343 ng/L for a species sensitivity
distribution (SSD) of EE2, highlighting the high potency of this API.
The bioconcentration of steroids is yet further complicated by the possibility that uptake is being
augmented by facilitated transport to yield tissue levels far beyond what would be predicted with
existing models assuming passive brachial uptake.
A study using the three-spined stickleback (Gasterosteus aculeatus) used 6-day static exposure
concentrations of I iJg/L (nominal) of either E2, testosterone (T), or E2 and T combined (Maunder
et al. 2007). Plasma levels climbed rapidly within the first 6 h to within the range of 20-90 ng/mL.
These bioconcentrated levels were 50-fold (E2) and 200-fold (T) greater than the measured exposure concentrations. The authors postulated that the faster and greater uptake than predicted of E2
and T might be due to the presence of a plasma sex hormone-binding globulin (SHBG). Scott et al.
(2005) also postulated that SHBG is responsible for enhanced uptake of many of the steroids. This
hypothesis is set forth in more detail by Miguel-Queralt and Hammond (2008).
Miguel-Queralt and Hammond (2008) report that natural and synthetic estrogens and androgens
are actively taken up by fish via the gills by way of binding to SHBG in the brachial filaments. This
uptake mechanism is extremely fast, with up to 70% of T or EE2 being removed from water in 90
min. A broad range of steroids have a high affinity for fish SHBG, whose ligand specificity varies
widely across species. Trace amounts (e.g., 50 pmol) of ligand can be taken up from water within
minutes. After uptake, residues are rapidly distributed throughout the body; EE2 was reported to then
accumulate in the brain, ovaries/eggs, and muscle. The authors point out that SHBG also has a high
affinity for at least two of the more common progestin APIs-levonorgestrel and 19-norethindrone.
Since these APls may be frequently present in sewage-derived waters, sometimes at relatively high
concentrations, this points to the possibility of progestins occurring in fish. Progestins, however, have
only rarely been targeted in environmental monitoring. Sediments in Puget Sound were analyzed for
the synthetic progestogen 19-norethindrone. Levels ranged from 419 to 890 ng/g, but the analysis was
done with GC-FlD rather than GC-MS (Kimball 2008). 19-Norethindrone was the most frequently
detected and abundant (26-224 ng/L) of all the synthetic estrogens/progesterones in sewage influent
samples (Fernandez et al. 2007). Lopez de AIda et ai. (2002) reported 19-norethindrone as frequently
occurring in sediments but at low ng/g-Ievels. Viglino et al. (2008) reported levonorgestrel and 19-norethindrone concentrations in sewage effluent ranging between 30 and 53 ng/L, respectively.
Others postulate that steroid residues in food may contribute more to bioaccumulation by fish
than do the residues at significantly lower concentrations in water. Takahashi et ai. (2003) report E2
concentrations ranging from 0.0001 to 0.0076 iJg/L in water, compared with 0.09-2.26 iJg/kg-wet
in the periphytons and less than 0.01-0.22 iJg/kg-wet in the benthos. Bioaccumulation factors of E2
were estimated at 64-1200 for the periphyton and 100-160 for the benthos.
It is important to note that even though the BCFs for EE2 do not indicate a propensity for bioaccumulation, the extremely low no-effect levels for this steroid have led a number of investigators to
recommend more detailed examinations (e.g., Lyssimachou and Arukwe 2007).
Direct uptake from water of El by Daphnia magna gave a BCF of 228 (Gomes et al. 2004);
biomagnification via feeding on C. vulgaris was not as efficient.

310

Environmental Contaminants in Biota

In a controlled study using artificial sediment and radiolabeled EE2, a benthic freshwater oligochaete (Lumbriculus variegatus) was exposed over 35 days to a nominal concentration of 300
ng/g wet-weight sediment (556 ng/g dry weight) (Liebig et al. 2005). Continuous linear uptake
never reached steady state. The BSAF was 75 after the 35 days. A calculated steady state (after 360
days of exposure) would yield a BSAF of 190-higher than predicted by Kow. A study with two
invertebrates-a midge (Chironomus tentans) and amphipod (Hyalella azteca)-followed 21-day
EE2 exposures using spiked water and water with sediments (Dussault et al. 2009). The exposure
concentrations, however, ranged up to 3.l ppm, orders of magnitude higher than those found in the
ambient environment. At one of the lower, but still high, water-only exposures (20 Ilg/L), the BCFs
were 31 for C. tentans and 142 for H. azteca; BSAFs were 0.8 and l.5, respectively.
8.2.6.8

Antibiotics: Informing Environmental Exposure with Data
from Use of Veterinary Aquaculture Drugs
APIs are used in aquaculture at levels many orders of magnitude higher than their occurrence in the
ambient environment. Exposure data in aquaculture settings are obtained usually to assess if therapeutic or prophylactic doses are reached and to assess subsequent depuration of residues to ensure
consumer safety. For this reason, the exposure concentrations are orders of magnitude higher than
ambient levels, and the antibiotics studied tend to be restricted to those used in veterinary practice
(although use of unapproved, illegal drugs also occurs). An overview of antibiotics used in aquaculture
is provided by Sapkota et al. (2008). In a Canadian Total Diet Study focused on residues of 39 different
veterinary drugs, levels tended to be in the range of low nanograms per gram (Tittlemier et al. 2007).
Even though exposures emulating those during aquaculture occur at higher ambient levels of
APIs, they might be useful as worst-case scenarios to inform the potential for bioconcentration
under ambient conditions. As one example, trout raised in aquaculture receiving medicated feed
with roughly 0.6% oxytetracycline (OTC), which yielded a maximum water concentration of about
0.8 ppm, reached a maximum muscle-tissue concentration of 1.8 ppm (Bebak-Williams et al. 2002).
This maximum level rapidly dissipated once the aqueous concentration dissipated. This shows that
at high exposure concentrations, the muscle-tissue level shows very little bioconcentration. The
literature on veterinary drug exposure is comparatively large, just two examples being Hou et al.
(2003) and Chu et al. (2008), who examined the uptake into muscle and depuration of sulfamethazine and nitrofurans.
The study of aquatic exposure to APIs actually began several decades ago. The study of antibiotics used in aquaculture led to the need for examining aquatic tissue levels to assess therapeutic dose
levels while assuring levels were sufficiently low for human consumption via the food supply. But
even then, the potential for environmental impacts was also a consideration; the early work of Coats
et al. (1976) using model ecosystems is an example.
Early studies on the environmental fate and possible biomagnification of veterinary drugs, particularly parasiticides, antibiotics, and other biocides, began in the 1960s and 1970s. Many of these
studies were comprehensive and generated considerable data, as they used traditional radiolabeled
materials to try and reach closure around mass balances. For example, 3-day uptake in fish of four
veterinary drugs was studied in aquatic model ecosystems, using radiolabeled anthelmintic phenothiazine, the coccidiostat clopidol, the bacteriostat sulfamethazine, and the growth promoter diethylstilbestrol (Coats et al. 1976).
Another route of exposure as a result of aquaculture, however, occurs because 70-80% of the
APIs used in medicated feed are released to the ambient environment as a result of excretion or
escape by way of feed that is not consumed (Pouliquen et al. 2009). Native fish in the vicinity can
then be unintentionally exposed-to levels exceeding ambient background concentrations. Usage
of antibiotics in aquaculture, however, is episodic and occurs for very limited number of days, but
concentrations in sediments immediately below can exceed the ppm-level (Pouliquen et al. 2009).
Samuelson et al. (1992) reported that levels of several antibiotics in aquatic organisms nearby aquaculture exceeded levels considered safe for human consumption; also see Cabello (2006).
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Blue mussels (Mytilus edulis) were evaluated for their ability to bioconcentrate two veterinary
antibiotics: OA and OTC (Le Bris and Pouliquen 2004). Exposure concentrations were intended to
emulate unintended exposure by what might be encountered near aquaculture. Exposure concentrations were roughly 0.95 mg/L for OTC and 1.46 mg/L for OA. Uptake was determined for foot,
muscle, mantle, viscera, gills. and shell. OTC concentrations were higher in viscera (1.83 mg/kg)
than gills (0.37 mg/L), with other parts less than 0.2 mg/kg. OA concentrations were highest in gills
(0.79 mg/kg) followed by shell (0.19 mg/kg). BAFs less than 1.0 were expected for these two highly
ionized APls.
Nie et al. (2008) found the bioaccumulation of ciprofloxacin by carp (Allogynogenetic crucian)
under controlled feeding conditions to vary greatly, depending on several exposure scenarios.
Feeding resulted in much higher residues (in visceral and muscle tissues) than via exposure to
water. Uptake was fast, with maximum levels being reached within a day. The tissue concentrations
(j1g/kg) resulting from each type of exposure were: water (muscle: 10; viscera: 42); feeding (muscle:
73; viscera: 645); and dual exposure (muscle: 43; viscera: 368).
8.2.6.9 Carbamazepine (CBZ)
Juvenile rainbow trout were exposed under continuous flow for 96 h to 200 j1g/L CBZ (Huggett
et al. 2004). After 24 h of exposure, the plasma concentrations of CBZ decreased, beginning at
about 2.5 ng/mL and ending at less than 1 ng/mL, showing a low propensity to bioconcentrate. See
the results for CBZ published by Ramirez (2007), Ramirez et al. (2007), and Zhou et al. (2008) summarized under the section "Multianalyte Studies." In those studies, CBZ was also shown to poorly
bioconcentrate, having a low BCF (<1).
After a 60-day exposure to a high 19-ppm concentration of CBZ, no intracellular accumulation
could be detected in the algae Ankistrodesmus braunii (Andreozzi et al. 2002). A method developed for determining CBZ in tissues was used to analyze a crustacean (Thamnocephalus platyurus)
after it fed on algae (Pseudokirchneriella subcapitata) that had been previously exposed to CBZ
at 250 mg/L (Lajeunesse et al. 2009). The mean CBZ concentration in dried T. platyurus was 129
(±57) j1g/mg.
8.2.6.10

Triclosan (and Methyl Triclosan) and Triclocarban
With respect to the most heavily used biocides, triclosan [TCS: 5-chloro-2-(2,4-dichlorophenoxy)phenoll has been studied more frequently than triclocarban [TCe: N-(4-chlorophenyl)-N'(3,4-dichlorophenyl)urea]. In general, the transformation of triclosan to the more lipophilic methyl
triclosan (MTCS: 4-chloro-I-(2,4-dichlorophenoxy)-2-methoxybenzene) leads to lower tissue levels
of TCS compared with MTCS. Most of the research has been conducted in Europe and Scandinavia,
with very recent studies in the United States (e.g., Leiker et al. 2009). Tissue residue levels of MTCS
generally exceed those of any API-a result of higher BCFs and higher exposure levels.
MTCS was first identified in fish by Miyazaki et al. (1984). Up to 38 ng/g was detected in the
whole bodies of a freshwater fish (Carassius carassius) collected from Tama River, Tokyo Bay.
Sams0e-Petersen et al. (2003) report on a monitoring study that sampled various aquatic species
from 12 locations in Sweden, where concentrations ranged from less than 0.1 to 13 j1g/kg (wet
weight). Much lower concentrations (in blood plasma) were reported in perhaps the first study from
the United States, where Alaee et al. (2003) reported on fish from the Detroit River (MichiganOntario) having TCS in the blood plasma of all 13 species surveyed; levels ranged from 0.61 ng/g
wet weight (brown bullhead) to 10.4 ng/g (white bass). In contrast, MTCS was detected in the plasma
of all 13 species but ranged only from 0.0004 ng/g for common carp to 0.0132 ng/g for largemouth
bass; the presence of TCS at 3 orders of magnitude higher concentration than MTCS was ascribed
to the higher lipophilicity of MTSC and its possible preferential partitioning to lipid tissue.
Bile was analyzed for TCS in fish subjected to various exposure scenarios involving three
WWTPs in Sweden, ranging from caged within effluent-dominated flows, to wild (or directly
exposed to sewage under controlled compositions) (Adolfsson-Erici et al. 2002). Concentrations
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ranged from 0.24 to 4.4 mg/kg bile (for wild fish) to 34-120 mg/kg (for those exposed directly to
treated sewage effluent).
Orvos et a1. (2002) assessed TCS bioconcentration in zebrafish (Dania reria) using continuous
flow with 3 and 30 Ilg/L for 5 weeks followed by 2 weeks of depuration. During the 5-week exposure, the BCFs ranged between 2000 and less than 3500 for the 39-llg/L exposure and from 3500 to
about 5200 for the 3-llg/L exposure, giving average BCFs during the exposure period of 4157 at 3
Ilg/L and 2532 at 30 Ilg/L. BCFs for head/scale and fillet ranged from about 1000 to 2000, whereas
they ranged from about 8000 to 11,000 in the intestines for the low and high exposures, respectively.
After depuration, the BCFs were 30 and 41 for the high and low exposures, respectively, so half-life
residence time within the body was short compared with POPs.
Boehmer et a1. (2004) performed a rare 10-year retrospective study (1994-2003) of breams
(A. brama) from representative German rivers. The study revealed that TCS was rarely present
in muscle while MTCS was detected in all specimens collected. In general, when present, TCS
muscle-tissue concentrations remained relatively constant but low for any given river-less than
1 ng/g wet weight. TCS concentrations were always lower than MTCS, which had excursions above
30 ng/g wet-weight muscle.
Balmer et a1. (2004) reported MTCS in fish (white fish, Careganus sp.; roach, R. rutilus) from
various lakes in Switzerland receiving treated sewage effluents. Concentrations ranged up to 35
ng/g (wet weight) or 365 ng/g (lipid basis) and fell within narrow ranges for a given lake. In another
study of Swiss lakes, Balmer et a1. (2005) measured lipid levels of MTCS in fish lipids, where levels
(ng/g) ranged from undetectable (perch) and 4-233 (roach), to 4-56 (whitefish). Buser et a!. (2006)
examined the muscle tissue of brown trout (Salma truttafario), from seven Swiss rivers that receive
treated sewage effluent, for MTCS. All concentrations were higher than those reported by Balmer
et a!. (2005) for lake fish (white fish, Caregonus sp. and roach, R. rutilus). Concentrations ranged
from 130 to 2100 ng/g, compared with the previous lake fish study of 4-370 ng/g. The concentrations for river fish had considerable variation, possibly due to a more fluctuating input from sewage;
river fish had higher concentrations probably because the exposure levels were higher.
In a recent study, a survey of common carp from Las Vegas Bay revealed MTCS (but not TCS) in
all 29 male common carp at a mean whole-body concentration of 600 Ilg/kg wet weight (7400 Ilg/kg
on the basis of lipid, giving a BCF of 1.8 x 105 ) (Leiker et a1. 2009). Three chlorinated analogs (3- and
5-chloromethoxy triclosan and 3,5-dichloromethoxy triclosan) were also present but less often and at
lower concentrations, ranging from 0.5 to 13llg/kg in 21-76% of the samples; the brominated analog
(bromomethoxy triclosan) was detected but not quantified.
In contrast with MTCS, reported TCS levels are not as common and almost always lower (with
the exception of blood plasma). The average TCS accumulation factor for zebrafish over a 5-week
test period was 4157 at 3 mg/L and 2532 at 30 mg/L (Orvos et a1. 2002). TCS concentrations were
highest in the digestive tract; head and muscle concentrations were similar. Following a 2-week
depuration, the average BAF was 41 for 3 mg/L exposure and 32 for 30 mg/L exposure. The BCF
was predicted to be roughly 2500.
Houtman et a!. (2004) identified TCS at ppm levels in the nonpolar residual fraction of bile from
wild fish in the Netherlands. Bile concentrations were about 14 Ilg/mL for fish from the North Sea
Canal and 80 Ilg/mL for fish from the River Dommel.
In a rare cross-species survey, TCS and MTCS were measured in the blood plasma of 13 species
of fish (both benthic and pelagic) from a stretch of the "highly contaminated" Detroit River (Valters
et a1. 2005). TCS levels ranged from 0.750 to 10.0 ng/g, while MTCS was present at 0.4-13.4 pg/L,
3 orders of magnitude lower. TCS in the estuarine water samples averaged 7.5 ng/L, although the
tissue and water sampling were temporally disconnected. Another feature of this study was the
parallel analyses for a spectrum of brominated diphenyl ethers.
Algae were shown to bioconcentrate TCS, MTCS, and TCC (Coogan et a!. 2007) by roughly
3 orders of magnitude when collected from Pecan Creek, the same effluent-dominated stream in
north Texas, U.S., previously studied by Brooks et a!. (2005) and Ramirez et a!. (2007). This may

Active Pharmaceutical Ingredients and Aquatic Organisms

313

be the first report of the bioconcentration of any of these three chemicals in algae; it may also be the
first report of the bioconcentration of TCC by any organism. Dissolved concentration ranges (and
algal wet-weight bioconcentration ranges and BAFs, Llkg) from four sampling sites for each of the
three analytes were: TCS levels of <10-120 ng/L «10-146 Ilg/L; BAFs nil-2100); MTCS levels of
<5-80 ng/L «5-89Ilg/L; BAFs nil-1500); and TCC levels of <15-190 ng/L (<10-401Ilg/L; BAFs
nil-2700).
Coogan and La Point (2008) extended these initial algal bioconcentration studies to examine
snail (Helisoma trivolvis) bioaccumulation of TCS, MTCS, and TCC from the effluent outfall to
Pecan Creek. Dissolved concentration ranges (and snail wet-weight bioconcentration level and
BAFs) were: TCS level of 112 ng/L (58.7 Ilg/L; BAF 500); MTCS level of 41 ng/L (49.8 Ilg/L;
1200); and TCC 191 ng/L (299 Ilg/L; 1600). Bioaccumulation of antimicrobials has been observed
in other macroinvertebrates; adult grass shrimp accumulated MTCS after a 14-day exposure to 100
Ilg/L TCS (Delorenzo et al. 2008).
More recently, Mottaleb et al. (2009) reported mean (n = 11, ±SD) TCS levels at 21 ng/g (±4) in
L. macrochirus (bluegill) from Pecan Creek, Texas. Although TCS was not detected in fish (Sonora
sucker) collected from a relatively pristine location in the East Fork Gila River, New Mexico, TCS
was detected at 12 ng/g in bluegill from Clear Creek, Texas, a regional reference site studied by
Brooks et al. (2005) and Ramirez et at. (2007). This site does not receive point-source municipal effluent, but may be influenced by onsite wastewater. In the Mottaleb et al. (2009) study, fish
samples examined from Pecan Creek were the same organisms analyzed previously for target APIs
by Ramirez et al. (2007).
The most in-depth controlled study of TCC involved its uptake from sediments by the freshwater oligochaete L. variegatus (Higgins et al. 2009); depuration was also studied. TCC BSAFs
were calculated and determined empirically during a 56-day study. Sediment spiked with TCC
maintained a constant (and environmentally relevant) concentration over 56 days (22.4 ± 7.6 Ilg/g
dry weight); the TCC concentration in the surrounding water also maintained constant, at 820 ± 220
ng/L. Uptake by L. variegatus was rapid, reaching a maximum of 1310 ± 60 Ilg/g lipid or 42 ± 2llg/g
wet weight at 5 days, after which levels began to decline. Bioaccumulation comported with predictions from conventional models. Depuration was rapid. After 21 days in clean sediment, the TCC
concentration in L. variegatus had declined to 9.6 ± 0.3 Ilg/g lipid (0.31 ± O.01llg/g wet weight). The
BSAF ([mass of sediment organic carbon]/[mass of tissue lipid organic carbon]) after 56 days was
calculated as l.6 ± 0.6.
In a very rare study of higher-tropic-Ievel aquatic wildlife, triclosan was measured for the first
time in a marine mammal-bottlenose dolphins (Tursiops truncatus) from two estuarine sites
(Charleston, South Carolina, and Indian River Lagoon, Florida) (Fair et al. 2009). Both sites are
influenced by discharged treated wastewaters. Blood-plasma levels ofTCS for one site ranged from
0.12 to 0.27 ng/g (with 4 of the 13 having levels exceeding the MDL of 0.033 ng/g), and for the other
site ranged from 0.085 to 0.106 (with 3 of 13 having detectable levels). These are possibly the highest
plasma levels yet reported for any aquatic organism. TCS levels in the respective waters for the two
sites averaged 7.5 ng/L, with a maximum of 13.7 ng/L.

8.2.6.11

Miscellaneous APls

In perhaps its first reported occurrence in fish from the wild, diazepam was quantified in liver
samples from 10 hornyhead turbot (Pleuronichthys verticalis) collected near MWTP ocean discharges in southern California (Kwon et al. 2009). The levels in five females ranged from 23 to
45 ng/g (wet weight) and in five males from 58 to 110 ng/g (wet weight); EE2, CBZ, simvastatin, and
oxybenzone were also targeted but not detected.
Malachite green is a multiuse chemical. Although it has useful properties in aquaCUlture, its use
in food is prohibited worldwide (see Sudova et al. 2007); nonetheless, it still experiences clandestine use in aquaculture and can be used legally for ornamental fish. Because it is a chromophore, it
also has a variety of other commercial uses unrelated to veterinary medicine-particularly as a dye.
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Malachite green bioconcentrates readily in the lipid of aquatic organisms, primarily as its metabolite leuco malachite green, which occurs at a ratio of 5-7:1. It persists in tissues, being found in the
highest concentration in the liver. Schuetze et al. (2008) documented the occurrence of malachite
green in the European eel (Anguilla anguilla L.) from lakes, rivers, and a canal in Berlin, Germany.
Total concentrations of malachite green and the leuco form ranged up to 0.765 f./g/kg (wet weight) in
25 of the 45 eels collected. Exposure was concluded to result from treated sewage. Although some
of the bioconcentrated residue may have come from the use of malachite green for illegal and legal
treatment of fish, an unknown but possibly large portion undoubtedly resulted from other commercial uses, such as dyed textiles.

8.2.6.12 API Disinfection By-Products CDBPs) and Metabolites
Chlorination of either drinking water or wastewater containing steroids is known to produce monoand di-chlorinated products of varying estrogenic activity. Little has been published on DBPs from
APIs. In the presence of bromide, which often occurs in surface waters and wastewaters, multiplybrominated analogs can be formed (Lu and Korshin 2008). In particular, Lu and Korshin (2008)
demonstrated the formation of stable dibromo-EE2. Buth et al. (2007) identified a number of products from the reaction of cimetidine with chlorine; Dodd and Huang (2004) identified products from
sulfamethoxazole; and DellaGreca et al. (2009) identified various chlorinated and nonchlorinated
products from atenolol. Similarly, Nakamura et al. (2007) identified a number of chlorinated estrones.
The bioaccumulative potential for these reaction products is unknown. Similar issues surround the
complex array of potential metabolites and other transformation products from parent APIs; many
examples are reviewed by Farre et al. (2008) and by Kosjek and Heath (2008). Little work has been
published on the possible metabolites from aquatic organisms. The recent work of Mehinto et al.
(2010) revealed some possible metabolites from diclofenac in fish.
Despite an increasing number of studies on API DBPs and other transformation products, there
are very few studies regarding their uptake by aquatic organisms. In one of the only such studies,
roach (R. rutilus) were exposed for 5 days in an aquarium filled with drinking water and spiked
with EE2 at a nominal concentration of 30 ng/L; the measurable concentration in the test situation,
however, was below the limit of detection (0.6 ng/L) (Flores and Hill 2008). EE2 was found to be
rapidly brominated (yielding mono- and di-brominated EE2). Di-brominated EE2 (but no detectable mono-brominated EE2) accumulated in the ovaries and liver to levels 18- to 67-fold greater
than the parent EE2. Concentrations (ng/g wet weight) ofEE2 and dibromo-EE2 detected were: liver
(EE2: 2.7 and dibromo-EE2: 92.3) and ovaries (EE2: 0.2 and dibromo-EE2: 2.3), yielding a BCF for
the ovaries of 130 and for the liver of 7894.

8.2.7

UPTAKE BY AQUATIC PLANTS AND AERIAL INVERTEBRATES

The uptake of APIs by plants and algae, which compose an important part of the aquatic food chain,
might prove a significant part of dietary exposure. Indeed, uptake of APIs by certain plants is so
efficient that they have been evaluated for in-situ phytoremediation of contaminated waters and
sediments (e.g., Forni et al. 2002). Plant uptake has been particularly germane to aquaculture sites.
A discrete body of work has been published on the uptake of APls by aquatic plants. The aquatic
bryophyte Fantinalis antipyretica is known to bioconcentrate metals, pesticides, and PAHs and
has therefore been used in situ as a bioindicator for integrative monitoring. A study of the uptake
of three antibiotics widely used in aquaculture (OA, flumequine, and OTC) showed BCFs ranging from 75 (flumequine) to 450 (OTC) (Delepee et al. 2004). These antibiotics had mean tissue
residence times of 18 and 59 days. The study was conducted at relatively high concentrations of
100 and 1000 ppb. BCFs were higher at the lower concentrations and were an inverse function of
K"w-increasing according to ionization instead of lipophilicity.
In a study of transpiration stream concentration factors (TSCFs) versus polarity, Dettenmaier
et al. (2009) showed that polar but nonionizable, highly water soluble organic compounds can be

Active Pharmaceutical Ingredients and Aquatic Organisms

315

easily taken up by plant roots and translocated to shoot tissue. Studies on uptake of APls by plants
(primarily bryophyte) have generally revealed rather high levels, and sometimes the source was
not necessarily related to aquaculture, as upstream samples have at times shown similar levels.
Pouliquen et al. (2009) examined bryophytes as biomonitors downstream of aquaculture and sewage. They reported maximum tissue concentrations (ng/g) for OA (47), flumequine (-600), OTC
(1200), and florfenicol (513).
Migliore et al. (2000) exposed an aquatic weed (Lythrum salicaria L.) to flumequine. After
35 days, the dry-weight tissue concentrations were in the ppm range: 13.3, 8.7, 0.7, 0.3, and 0.2 Ilg/g at
flumequine aqueous concentrations of 5000, 1000,500, 100, and 50 Ilg/L, respectively. Exposure
of an aquatic fern (Azolla filiculoides Lam.) to sulfadimethoxine for 5 weeks at concentrations
of 50, 150,300, and 450 mg/L resulted in uptake at the mg/g dry-weight level (1000 ppm) (Forni
et al. 2002). Typha was shown to rapidly absorb clofibric acid at 20 Ilg/L, removing more than
50% within 48 h (Dordio et al. 2008).
Redshaw et al. (2008) recently used a Brassicaceae (cauliflower) model to examine fluoxetine
uptake by plants. Following a 12-week exposure to 280 Ilg/L fluoxetine in growth media, fluoxetine
concentrations were higher in the stems (0.49 Ilg/g wet weight) than in leaf tissues (0.26 Ilg/g wet
weight) of Brassicaceae. This study did not examine steady-state tissue levels of fluoxetine; this is
important because fluoxetine is photolabile and should have degraded over the 12-week study period
(Redshaw et al. 2008). However, presence of low Ilg/g-levels of fluoxetine suggest bioconcentration, which did not correlate with lipid content in leaf and stem tissues of Brassicaceae. Although
cauliflowers are terrestrial plants and this study was specifically interested in estimating potential
fluoxetine uptake in terrestrial plants exposed to biosolid-amended soils, it suggests that fluoxetine
accumulation by nonrooted aquatic macrophytes such as Lemna sp. should be considered (Redshaw
et al. 2008).
Coexposure to APls will often occur with varying nutrient ratios and stoichiometries. Nutrient
enrichment was previously demonstrated to influence the magnitude of triclosan toxicity to
L. gibba, for both traditional morphometric endpoints (Fulton et al. 2009) and nontraditional
responses, such as internal C:N:P and nitrate uptake kinetics (Fulton et al. 2010). Because nutrient
stoichiometry can also influence internal lipid metabolism and concentrations in plants and algae,
site-specific nutrient enrichment differences may result in differential bioconcentration of APls
(Fulton et al. 2010).
The potential for trophic transfer of APls out of the aquatic realm was recently shown by Park
et al. (2009). EE2 was determined in aerial invertebrates (primarily Diptera) whose larval stages
develop in STP percolating filter beds. EE2 concentrations in insects captured near STPs were significantly higher than in those over 2 km away. The median EE2 tissue concentration was 42 ng/g
(with the 75th percentile 140 ng/g) from insects near the STPs, compared with a median level of less
than 3 ng/g (and 9 ng/g 75th percentile level) detected in the insects more distant from the STPs.
Further transfer to insectivorous bats and birds was postulated. Rough calculations estimated that
daily exposure to EE2 for bats feeding on insects near the STPs could range from 9 to 159 ng/g.

8.2.8

MULTIANALYTE STUDIES

Studies that target multiple APls to gauge ambient exposure are indeed rare. The recent study of
Schultz et al. (2010) targeting 10 antidepressants (including two metabolic/transformation products)
was discussed earlier. The first and most comprehensive multianalyte study to date on fish tissue was
by Ramirez et al. (2007). From a target list of 23 APls and 2 metabolites, only four were reported as
being detected. Fish (Lepomis sp.) were sampled in Texas from an effluent-dominated stream (n = 11)
and from another creek (n = 20) that served as reference. The four APls were detected in muscle
from all samples in the study site. The range (and mean; ng/g wet weight) were: diphenhydramine
[0.66-1.32 (0.96)]; diltiazem [0.11-0.27 (0.21)]; CBZ [0.83-1.44 (1.16)]; and norfluoxetine [3.49-5.14
(4.37)]. This is the first report of diphenhydramine, diltiazem, and CBZ in wild fish.

316

Environmental Contaminants in Biota

With impetus provided by the Brooks et al. (2005) study, the U.S. EPA initiated the National
Pilot Project of pharmaceuticals and PCPs (PPCPs) in Fish Tissue (U.S. EPA 2008a), which represents the first national-scale reconnaissance study of PPCPs in fish tissue (Ramirez 2007, Ramirez
et al. 2009). Sample collection and processing procedures followed approaches previously used
during the U.S. EPA's National Study of Chemical Residues in Lake Fish Tissue. Analytical methods for PPCPs in the National Pilot Project employed approaches previously developed by Ramirez
et al. (2007) and Mottaleb et al. (2009). Because effluent-dominated and effluent-dependent ecosystems represent worst-case scenarios for API exposure (Brooks et al. 2006), five effluent-dominated
river systems were selected for study: Phoenix, AZ; Orlando, FL; Chicago, IL; West Chester, PA;
and Dallas, TX. The Gila River, NM was selected as a reference site for this study. Ramirez et al.
(2009) targeted 25 APTs/metabolites in the fillets and livers from wild-caught fish: acetaminophen,
atenolol, caffeine, CBZ*, cimetidine, clofibric acid, codeine, diltiazem*, 1,7-dimethylxanthine,
diphenhydramine*, erythromycin, fluoxetine*, gemfibrozil*, ibuprofen, lincomycin, metoprolol,
miconazole, norfluoxetine*, propranolol, sertraline*, sulfamethoxazole, thiabendazole, trimethoprim, tylosin, warfarin. The four shown in italics had MDLs below I ng/g. The seven with asterisks
were detected in multiple fish from multiple locations. Of these seven that were detected, three had
the lowest MDLs (CBZ, diltiazem, and diphenhydramine) in both fillet (less than I ng/g) and liver
(less than 2 ng/g), while only two (fluoxetine and gemfibrozil) were among those with the highest
MDLs (greater than 6 ng/g in fillet and 12 ng/g in liver). Of the seven APIs with the highest MDLs,
only one (gemfibrozil) was detected.
At only one of the five sites, receiving effluent from a sewage treatment facility using tertiary
treatment, none of the target APIs was detected in the fillet from any fish; also no API was detected
in any fish from a nonimpacted reference site. All of the seven APIs detected among the 25 targeted
APIs were detected in fish from only one site, which received effluent from secondary treatment.
Mean concentrations in fillet for all the detected APIs were generally less than 3 ng/g and ranged
from 0.04 to 11 ng/g. The majority of the mean concentrations in liver for all the detected APIs
were generally greater than 6 ng/g and ranged from 0.03 to a high of 380 ng/g (sertraline). Except
for one site where fluoxetine was found in fillet but not in liver (and where the liver also contained
substantially more norfluoxetine), the APT concentrations in livers were always larger-by several
fold or by over one order of magnitude. Of significance, API concentrations did not correlate with
lipid content-a finding shared with other published studies.
Another study targeted five APIs during the course of ground truthing a new in vivo tissue sampling method using implanted solid-phase micro extraction (SPME) fibers (Zhou et al. 2008). The targeted APIs were the ones previously reported by Ramirez et al. (2007): diltiazem, diphenhydramine,
CBZ, and norfluoxetine. Under controlled exposure conditions, rainbow trout (0. mykiss) gave BCFs
for CBZ in muscle after 7- and 14-day exposures of 0.44 and 0.22, respectively. Significantly, free and
total tissue levels after 14 days were lower than those after 7 days. The authors postulated that CBZ
metabolism was upregulated during the exposure time. The bioconcentration of fluoxetine differed
markedly. While the respective free concentrations in muscle after 7 and 14 days of exposure were
only 0.30 and 0.65 times those in the aqueous media, the BCFs for total fluoxetine in muscle were 62
and 84, respectively. The same approach was used for determining muscle levels of free API in wild
fish captured from streams that received treated sewage. These are the only reports of "free" APIs in
aquatic tissues. In the wild fish, only diltiazem and diphenhydramine were detected. Free diltiazem
muscle concentrations were 2.04 and 5.69 pg/g in the white sucker (c. commersoni) and Johnny darter
(Etheostoma nigrum), respectively. Free diphenhydramine concentrations were 32.0 and 81.6 pg/g for
white sucker and Johnny darter, respectively. These concentrations are several orders of magnitude
lower than the conventional "total" levels reported by all previous investigations.
A more recent study (Fick et al. 2010), which was built on previous efforts by Brown et al.
(2007), exposed rainbow trout to final treated effluent for 14 d at three different sites in Sweden
(Umea, Stockholm, and Gothenburg). Of the 25 API analytes targeted, 16 were detected in fish
plasma (sampled from at least one study location) at levels exceeding one-thousandth of their
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respective human plasma levels associated with therapeutic dose (CmaJ. One of these 16 APTs of
particular significance was the synthetic progestin levonorgestrel-at plasma levels of 8.5 and 12 ngl
mL, a level4-fold greater than human plasma Cmax . This plasma level of levonorgestrel represented
an empirical BCF of 12,000, which was 200-fold higher than the predicted BCF. Such approaches
for relating internal-dose API exposures to potential effect thresholds are explored further below.
Finally, the study of Kwon et al. (2009), as discussed earlier, targeted five APIs: EE2, diazepam,
CBZ, simvastatin, and oxybenzone. Only the first two, however, were detected in liver samples from
hornyhead turbot (P. verticalis) from southern California.

8.2.9

SUMMARY OF PUBLISHED DATA

Much of the data for APIs/metabolites and related DBPs in this chapter on aquatic tissue-levels and
BCFs/BAFs compiled from the published literature is summarized in Table 8.4. Included in the
table is an indication of historical precedence-whether the data were the first to be reported; most
of the data are "firsts," revealing that the depth of the published data in terms of repeated measurements is very shallow.

TABLE 8.4
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk*)

Maximum
Concentration in
Wild Specimens
(Ilglkg) (Controlled
Studies Indicated
by Asterisk*)

Bupropion

0.013-0.07 brain

Citalopram

0.57 plasma
0.01-0.07 brain

Pluoxetine

1.58 brain
1.34 liver

0.02-0.6 brain

Historical
Precedence in
Literature

Notes

Antidepressants
Probably I st
Detected in samples from 5 of 8
streams; upper range = 0.348
report
ng/g. Water = 20-50 nglL.
Possibly 1st
report
Probably 1st
report
Probably J st
reports

Reference

Schultz et a1.
(2010)

Sharks.

Gelsleichter
(2009)

Detected in samples from 4 of 8
streams; upper range = 0.212
ng/g. Water = 4.5-70 ng/L.
Lowest concentrations in
muscle. Empirical BCFs up to
260 for body and 3100 for
liver (Nakamura et a1. 2(08);
but BCF for "free" ftuoxetine
less than unity (Zhou et a1.
2008). Controlled exposure to
0.55 gIL gave peak
concentration of 49 flg/kg
tissue (Paterson and Metcalfe
2008).
Detected in samples from 6 of 8
streams; upper range = 1.6
ng/g. Water = 1-9 ng/L.

Schultz et a1.
(2010)
Brooks et a1.
(2005) [also
Chu and
Metcalfe (2007)]

Schultz et a1.
(2010)
continued
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk*)
Norfluoxetine

Maximum
Concentration in
Wild Specimens
(J.Ig/kg) (Controlled
Studies Indicated
by Asterisk*)
10.27 liver
8.86 brain

Historical
Precedence in
Literature
Probably 1st
reports

0.07-0.9 brain

Paroxetine

0.58 whole body

Probably 1st
report

0.005-1.8 brain

Sertraline

4.27 brain
3.59 liver
1.1-1.2 plasma

Probably 1st
reports

Norsertraline

15.6 brain
12.94 liver
0.01-3 brain

Probably 1st
reports

0.01-0.02 brain

Venlafaxine

0.32 plasma

Possibly 1st
report

0.02-0.1 brain

Diclofenac

12 plasma

Detected in samples from 6 of 8
streams; upper range = 4.2
ng/g. Water = 2-4 nglL.
Lowest concentrations in
muscle.
Fish exposed to treated sewage
effluent; 2 of 3 sites in
Sweden; BCF > 138-240
(predicted = 959).
Lowest concentrations in
muscle.
Detected in samples from 7 of 8
streams; upper range = 28.9
ng/g. Water = 1.1-6 nglL.
Detected in samples from 3 of 8
streams; upper range = 0.113
ng/g. Water = 0.8-4 nglL.
Sharks.
Detected in samples from 2 of 8
streams; upper range = 1.12
ng/g. Water = 102-220 nglL.

NSAIDs
Probably 1st
report

2.2-20 plasma

328 bile

Notes
Lowest concentrations in muscle.
Controlled exposure to 0.55
nglL of fluoxetine gave peak
concentration of 64 /lg/kg tissue
(Paterson and Metcalfe 2008).
Detected in samples from 5 of 8
streams; upper range = 3.6
ng/g. Water = 0.9-4 nglL.

Probably 1st
report in bile

BCF = 5. First report of
bioconcentration (under
controlled conditions) gave mgl
kg concentrations in liver and
kidney, with BCFs of nearly
3000 [Schwaiger et al. (2004) J.
Fish exposed to treated sewage
effluent; 3 of 3 sites in Sweden;
BCF = 2.5-29 (predicted = 93).
21-day exposure of trout to
0.5 ng/mL; BCF = 657.

Reference
Brooks et al.
(2005) [also
Chu and
Metcalfe (2007)]
Schultz et al.
(2010)
Chu and Metcalfe
(2007)
Schultz et al.
(2010)
Brooks et al.
(2005)
Fick et al. (2010)

Brooks et al.
(2005)
Schultz et al.
(2010)
Schultz et al.
(2010)
Gelsleichter
(2009)
Schultz et al.
(2010)

Brown et al.
(2007)

Fick et al. (2010)

Mehinto et al.
(2010)
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk*)

Maximum
Concentration in
Wild Specimens
(Ilglkg) (Controlled
Studies Indicated
by Asterisk*)

Ibuprofen

84 plasma

Historical
Precedence in
Literature
Possibly 1st
report

S.S-102 plasma

Ketoprofen

Undetected

IS-I07 plasma

Naproxen

14 plasma

Probably 1st
attempted
analysis
Probably 1st
report

Probably 1st
report

Notes
BCF= 18,667.
Fish exposed to treated sewage
effluent; 3 of 3 sites in
Sweden; BCF = 21-S8
(predicted = 77).
Did not bioconcentrate.

Fish exposed to treated sewage
effluent; 3 of 3 sites in
Sweden; BCF = 3.S-48
(predicted = 20).
BCF = S6.

33-46 plasma

Lipid Regulators

Gemfibrozil

f1-Blockers

Atenolol*

Propranolol *

Nine triazoles*

Reference
Brown et al.
(2007)
Fick et al. (2010)

Brown et al.
(2007)
Fick et al. (20 I 0)

Brown et al.
(2007)
Fick et al. (2010)

Fish exposed to treated sewage
effluent; 3 of 3 sites in
Sweden; BCF = 22-28
(predicted = 24).
Calculated BCFs for a number of fibrates and statins are provided by Hernando et al. (2007);
values ranged 120--380 for clofibrate, fenofibrate, lovastatin, and mevastatin, but higher for
simvastatin (800) and ftuvastatin (2000).
Brown et al.
210 plasma
Probably 1st
BCF = 199. Plasma
(2007)
report
concentration of 170 Ilg/L
yielded a BCF of SOO after
controlled exposure to 0.34
IlglL (Mimeault et al. 200S).
Not detected in studies of
Brooks et al. (200S) and
Brooks (unpublished data).
Probably 1st
Controlled exposure to
Winteret al.
SI plasma*
report (for
(2008)
3.2 mglL. Calculated BCF
controlled
diminishingly low (Cleuvers
exposure)
200S).
Probably 1st
Controlled exposure to 10 mglL
Owen et aI.
S plasma*
(2007; also
report (for
for 10 days.
unpublished
controlled
exposure)
data)

SOO-IOOO body
lipid*

Fungicides
Probably 1st
Exposed via feed at
report (for
concentrations of
23-3S mg/kg w/w.
controlled
exposure)

Konwick et al.
(2006)

continued
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk*)
Macrocyclic
Lactones
(avermectins)
Abamectin*
Avennectin Bla*

Maximum
Concentration in
Wild Specimens
(lig/kg) (Controlled
Studies Indicated
by Asterisk*)

Historical
Precedence in
Literature

38.29 muscle*
6.8. 3.0, and II * in
whole fish, fillet,
and viscera

One of earliest
reports for
controlled
exposure

Steroids

EE2

1100 bile

Perhaps 1st
bioconcentration
study

3.79 plasma
EE2*

31 tissue*

Perhaps the first
full life-cycle
bioconcentration
study ofEE2

32--40 (E2eq) bile*
EE2 dibrominated*

92.3 liver*
2.3 ovaries *

Perhaps I st study
(controlled)
targeted at API
DBPs

Levonorgestrel

8.5-12 plasma

Probably 1st
report

Testosterone*

80 plasma*

Notes

Reference

Residues well-established as
occurring in liver and lipids.

See overview:
Danaher et al.
(2006).

Controlled 22-d exposure to
I /lg/L; BCF = 42.
Controlled 28-d exposure to
I /lglL; BCFs of 56, 28, and 84.

Shen et al. (2005)

Considerable data exist on
uptake of endogenous
estrogens under controlled in
situ conditions (not
summarized here).
4-week exposure in effluentdom inated stream; controlled
46-h exposure to 5 /lglL gave
350,000 /lglL in bile;
bioconcentration is in the
range of 4-6 orders of
magnitude.
Juvenile sharks in wild.
Lifecycle/posthatch exposure to
64 nglL. BCFs probably less
than 500-2400. No detectable
residues after exposure to
I nglL.
Also detected in testes and
ovaries.
Roach exposed for 5 days to
drinking water with
measurable EE2 of 0.6 nglL.
Accumulated concentrations
18-67 greater than those
measured for EE2. BCFs 7894
(liver) and 130 (ovaries).
Fish ex posed to treated sewage
effluent; 2 of 3 sites in
Sweden; BCF = 12,000
(predicted = 46).
6-day exposure to I /lglL;
plasma levels dropped quickly
upon cessation of exposure.

Van den Heuvel
et al. (1996)

See overview:
Tyler et al.
(2008).

Larsson et al.
(1999)

Gelsleichter
(2009)
Lange et al.
(2001)

Gibson et al.
(2005a)
Flores and Hill
(2008)

Fick et al. (2010)

Maunder et al.
(2007)
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk*)
Equilenin*

17~

Dihydroequilenin*

Antibiotics

Miscellaneous
Carbamazepine
(CBZ)

Maximum
Concentration in
Wild Specimens
(Ilg/kg) (Controlled
Studies Indicated
by Asterisk*)

Historical
Precedence in
Literature

Notes

Reference

Probably 1st
Tyler et al. (2009)
BCF = 2.2 x
report (for
exposure to
treated sewage)
3Q....40 (E2eq) bile*
Probably 1st
Gibson et al.
BCF = 1.5 x 106
report (for
(2005a,2005b)
exposure to
treated sewage)
Considerable data exist for tissue levels resulting from the high exposures used in aquaculture.
Some data exists from controlled studies that simulate the indirect exposure that might occur for
organisms in the vicinity of an aquaculture operation. See text for discussion.
106

2.5 plasma*

0.3~ 1.0

Perhaps 1st
report (for
controlled
exposure)

plasma

0.83~ 1.44

muscle

129,000* crustacean

Cilazapril

None detected in
algae
0.1~0.7 plasma

Diazepam

23~110

Diltiazem

0.11-0.27 muscle

liver

0.002~0.0056

muscle

0.9 plasma

I st report in wild
fish
Trophic-level
transfer

Possibly 1st
report

Possibly 1st
report
1st report in wild
fish
I st report of
"free"
concentrations
in wild

24-h exposure to 200 flglL;
BCF < I.

Huggett et al.
(2004)

Fish exposed to treated sewage
effluent; 3 of 3 sites in
Sweden; BCF = 0.8-4.2
(predicted = 6).
II specimens from effluentdominated stream.
Concentration on basis of dried
weight; fed algae that had been
exposed to CBZ.
Exposed to 19 ppm.

Fick et al. (201 0)

Fish exposed to treated sewage
effluent; 2 of 3 sites in
Sweden; BCF> 100-700
(predicted = 6).
CBZ and simvastatin also
targeted but not detected.
II specimens from effluentdominated stream.

Fish exposed to treated sewage
effluent; I of 3 sites in
Sweden; BCF = 24~ 139
(predicted = 14).

Ramirez et al.
(2007)
Lajeunesse et al.
(2009)
Andreozzi et al.
(2002)
Fick et al. (2010)

Kwon et al.
(2009)
Ramirez et al.
(2007)
Zhou et al. (2008)

Fick et al. (201 0)
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk')

Maximum
Concentration in
Wild Specimens
(Ilglkg) (Controlled
Studies Indicated
by Asterisk')

Diphenhydramine

0.66-1.32 muscle
0.032-0.082 muscle

Haloperidol

Meclozine
(meclizine)

Memantine

Orphenadrine

Oxazepam

Risperidone

Tramadol

Verapamil

Triciosan,
Methyl triciosan,
Triciocarban
TCS

1.2 plasma

Historical
Precedence in
Literature
1st report in wild
fish
I st report of
"free"
concentrations
in wild
Possibly 1st
report

Notes
II specimens from effluentdominated stream.

Fish exposed to treated sewage
effluent; 1 of 3 sites in
Sweden; BCF = 3.2 (predicted
= 153).
0.1-0.7 plasma
Fish exposed to treated sewage
Possibly 1st
effluent; 2 of 3 sites in
report
Sweden; BCF > 200-1400
(predicted = 2521).
2.3 plasma
Probably 1st
Fish exposed to treated sewage
effluent; I of 3 sites in
report
Sweden; BCF < 50-164
(predicted = 36).
0.9 plasma
Probably 1st
Fish exposed to treated sewage
report
effluent; I of 3 sites in
Sweden; BCF < 63-100
(predicted = 61).
0.2-0.7 plasma
Probably 1st
Fish exposed to treated sewage
report
effluent; 3 of 3 sites in
Sweden; BCF = 0.7-3.6
(predicted = 7).
0.3-2.4 plasma
Probably 1st
Fish exposed to treated sewage
report
effluent; 3 of 3 sites in
Sweden; BCF > 60-480
(predicted =47).
1.1-1.9 plasma
Probably 1st
Fish exposed to treated sewage
report
effluent; 3 of 3 sites in
Sweden; BCF = 2.3-3.3
(predicted = 20).
0.7 plasma
Probably 1st
Fish exposed to treated sewage
report
effluent; I of 3 sites in
Sweden; BCF < 33-175
(predicted = 40).
TCS: 5-chloro-2-(2,4-dichlorophenoxy)phenol
MTCS: 4-chloro-I-(2,4-dichlorophenoxy)-2-methoxybenzene
TCe: N -( 4-chlorophenyl)-N'-(3 ,4-dichlorophen yl )urea
0.61-10.4 plasma
1st report in U.S.
Detected in all 13 species
surveyed.

Reference
Ramirez et al.
(2007)
Zhou et al. (2008)

Fick et al. (2010)

Fick et al. (20 I 0)

Fick et al. (2010)

Fick et al. (2010)

Fick et al. (2010)

Fick et al. (2010)

Fick et al. (2010)

Fick et al. (2010)

Alaee et al.
(2003)
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
(Controlled In Situ
Studies Indicated
by Asterisk')

Maximum
Concentration in
Wild Specimens
(fig/kg) (Controlled
Studies Indicated
by Asterisk')

Historical
Precedence in
literature

0.75-10.0 plasma

TCS-halogenated
analogs

MTCS

85-270 plasma

1st report in
marine
mammal

240 to 4400 bile

Possibly 1st
report (in bile
of wild fish)

Notes
13 species from Detroit River.
MCTS levels 0.0004-0.013
Ilgikg, 3 orders of magnitude
lower.
Detected in 7 of 26 dolphins.
Possibly highest plasma level
reported for any aquatic
organism.

The Netherlands

35 whole body; 365
lipid
21 whole body

Swiss lakes

146 algae whole
body
58.7 snail whole
body
0.5-13 whole body

1st report in
snail

Algal BAF: <2100
Snail BAF: 500

I st report of
halogenated
products

3- and 5-chloromethoxy TCS;
3,5-dichloromethoxy TCS;
unidentified bromomethoxy
TCS; detected in 21-76% of
29 carp from Las Vegas Bay.

38 whole bodies

1st report

600 whole body;
7000 lipid
0.0004-0.0132
plasma
30 muscle

130-2100 muscle

1st report in U.S.

Fair et al. (2009)

Adolfsson-Erici
et al. (2002)

14,000-80,000 bile

0.1-13 whole
bodies

Reference
Valters et al.
(2005)

Monitoring study of multiple
species at 12 locations in
Sweden.
Detected in all 29 carp from Las
Vegas Bay. TCS not detected.
BCF = 1.8 x 105
Detected in all 13 species
surveyed.
I O-year retrospective study of
breams. MTCS was always
detected, but TCS was rarely
present.
Seven Swiss rivers

Houtman et al.
(2004)
Balmer et al.
(2004)
Mottaleb et al.
(2009)
Coogan et al.
(2007)
Coogan and La
Point (2008)
Leiker et al.
(2009)

Miyazaki et al.
(1984)
Sams0e-Petersen
et al. (2003)
Leiker et al.
(2009)
Alaee et al.
(2003)
Boehmer et al.
(2004)

Buser et al.
(2006)
continued
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TABLE 8.4 (continued)
Summary of Bioconcentration Data for APls in Aquatic Tissues
APls Studied in
Wild Specimens
{Controlled In Situ
Studies Indicated
by Asterisk*)

Maximum
Concentration in
Wild Specimens
(JIg/kg) (Controlled
Studies Indicated
by Asterisk*)

Historical
Precedence in
literature

4-233 lipid

TCC

Notes

Reference

Swiss lakes

Balmer et al.
(2005)
Coogan et al.
(2007)
Coogan and La
Point (2008)
Coogan et al.
(2007)
Coogan and La
Point (2008)
Higgins el al.
(2009)

89 algae whole body
49.8 snail whole
body

1st report in
snail

Algal BAF: <1500
Snail BAF: 1200

401 algae whole
body
299 snail whole
body
42,000 worm whole
body*

I st report in any
organism
I sl report of
BSAF

Algal BAF: <2700
Snail BAF: 1600
Worm BSAF: ca 2

Considering the data for all APIs (excluding triclosan and its derivatives) on aquatic tissue
levels or bioconcentration, the following can be noted. Only a handful of studies predate 2003. The
concentrations for the majority of APIs range from I to 100 /-lg/kg regardless of tissue type. Those
APls showing higher concentrations include gemfibrozil and triazole fungicides. Most data are for
controlled in situ exposures rather than for organisms sampled in the wild. Data for tissue levels
in wild samples exist for roughly 21 APIs and metabolites. Data for controlled studies exist for
about 9 APIs; the study of Fick et al. (2010) exposed fish to treated sewage effluent and quantified
an additional 10 unique APls. Data for tissue levels exist for roughly 40 human APIs/metabolites
(excluding antibiotics) but many are from single studies. Steroids are commonly quantified as
total (conjugates combined with free). Of the existing calculated empirical BCFs, except those for
steroids, nearly all are lower than several thousand, most being lower than 100. More data exist
for estrogens (especially endogenous estrogens) and triclosan (including MTCS and other derivatives) than for any other class of APIs; surprisingly, despite its high usage (similar to triclosan),
very little data exists for triclocarban. MTCS, unlike TCS, does not concentrate in plasma. Tissue
concentrations for both TCS and MTCS can exceed tens of thousands /-lg/kg, with BCFs up to the
range of several million.

8.3
8.3.1

FACTORS INFLUENCING EXPOSURE
GENERAL CONSIDERATIONS

It is important to keep in mind the difficulty in comparing BCFs between APIs (or even for a given

API) or between species of fish and other aquatic organisms. The wide range of variables in Table
8.3 can add tremendous variability to these values. But moreover, BCFs are reported on different
bases, not just whole body; these include different tissues or on a wet-weight basis or on the basis
of lipid content. They can also use empirical data generated by static (steady-state equilibration and
non steady-state) or kinetic uptake measurements, as well as nominal exposure levels that span one
or more orders of magnitude (sometimes exceeding the solubility, and other times the uptake rate is
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the limiting factor, resulting in lower BCFs at higher exposures). These factors make it difficult to
distill existing data into succinct generalizations.
Various models have been developed in attempting to link aquatic tissue residues with biological
effects. As an example, attempting to establish a more realistic measurable linkage of exposure with
effects, the CBR concept holds that the whole-body concentrations across species does not vary
wildly among chemical stressors sharing the same MOA for a given biological endpoint. The CBR
is supposedly relatively consistent for a given endpoint, whether acute or chronic. Its appeal derives
from the assumption that levels of chemical stressors internal to an organism more directly dictate
receptor interaction than doses calculated from surrounding ambient concentrations. By the nature
of its definition, CBR should be relatively independent of the stressor's ambient concentration in the
immediate aqueous environment. The CBR concept supposedly accounts for a measure that is more
closely associated with the level of stressor that would actually interact with the receptor. However,
in a critical examination of CBR by Barron et al. (2002), published data were not found to support
the CBR concept among members from groups of chemicals sharing the same MOA; variability in
correlation with effects was found to be as great as other measures such as ambient concentration.
Many variables may be at work here. For example, it is not known whether bioaccumulated residues
are readily bioavailable, or if rather, only the free residues are (e.g., Zhou et al. 2008).
These issues, together with the many terms used in aquatic exposure (e.g., bioconcentration, bioaccumulation, biomagnification, bioavailability, and biomarkers) and exposure's role in assessing
aquatic health, are discussed in the comprehensive work of Geyer et al. (2000), Gobas and Morrison
(2000), and van der Oost et al. (2003). What measure of stressor level experienced by an organism
serves as the best surrogate for true dose remains elusive. Below we examine several important
variables that may be critical for ecological risk assessments of APIs.

8.3.2

SELECT SITE-SPECIFIC FACTORS INFLUENCING EXPOSURE

8.3.2.1 Hydrology
Effluent-dominated ecosystems may be defined as receiving systems in which more than 50% of
the in-stream flow results from effluent discharges. Effluent-dependent conditions result seasonally
when the in-stream flow of these receiving systems is entirely dependent on effluent discharges. In
more arid or semiarid regions experiencing rapid urbanization, effluent-dominated or dependent
conditions are common (Brooks et al. 2006). Examples of effluent-dominated large river systems
include the Trinity River in Texas and the South Platt River in Colorado (Brooks et al. 2006).
Prospective environmental assessments of APIs often include a default in-stream dilution factor
of 10 when predicting expected environmental concentrations (Brooks et al. 2003), which are not
representative or protective of effluent-dominated or dependent ecosystems.
In an attempt to estimate effluent-dominated conditions in the United States, Brooks et al. (2006)
examined information from the U.S. EPA on receiving system critical dilution limits included in
the National Pollutant Discharge Elimination System (NPDES) program (U.S. EPA 1991). Under
annual mean flow, it was estimated that less than 20% of discharges entered receiving systems with
less than 1O-fold dilution, but this value increased three fold to approximately 60% of in-stream
dilution occurring at less than 10 fold during low flow conditions (e.g., 7Q1O, the seven consecutiveday lowest flow with a 1O-year recurrence interval) (Brooks et al. 2006).
The NPDES data summarized above was quite dated. New discharges or increased treatment
demands on existing dischargers frequently result from increasing population growth. Thus, Brooks
et al. (2006) examined a representative sample of NPDES permits (582) in U.S. EPA Region 6,
which comprises the states of Arkansas, Louisiana, Oklahoma, New Mexico, Texas, and a number
of Tribes. The minimum (or critical) dilution limit for a wastewater stream is the smallest degree of
dilution that can avoid reasonable potential to exceed water quality criteria. Of the permits examined during the late 1990s and early 2000s by U.S. EPA Region 6 staff, 58% included critical
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dilution limits of >50%, suggesting effluent-dominated or dependent conditions under low flows.
Critical dilution limits of 100%, indicating effluent-dependent conditions, were observed in 37% of
permits evaluated (Brooks et al. 2006).
As noted earlier, in-stream hydrology is an important consideration because effluent-dominated
conditions present worst-case locations for API exposures in developed countries. Daughton (2002)
proposed the term "pseudopersistent" to describe the unique exposure scenarios to APIs in these
ecosystems. Although APIs are designed to be stable enough to ensure parent stability through
the manufacturing-distribution-prescription-treatment continuum, APIs are generally considered to
have lower environmental persistence than conventional priority pollutants. However, human APIs
(and ingredients from PCPs) may be unique compared with conventional contaminants because
they can be continuously introduced via effluent to a receiving system (Daughton 2002). Under
these conditions the half-lives of the compounds may exceed in-stream hydrologic retention times,
increasing the effective exposure duration experienced by organisms residing in the receiving
system (Ankley et al. 2007). Of course, increased effective exposure duration could also apply to
other effluent contaminants in these scenarios. Unfortunately very little information is available for
in-stream magnitude, frequency, and duration of exposure to APIs originated from any of numerous
sources, so the influence of hydrology on "pseudopersistence" of APIs requires more study.

8.3.2.2 Wastewater Treatment Technologies
Though effluent-dominated or effluent-dependent conditions described earlier deserve particular
attention for API exposures in developed countries, treatment capabilities of WWTPs discharging
to these systems are likely to be relatively high because effluent dilution limits are generally more
stringent to meet effluent quality goals (e.g., water quality criteria, whole effluent toxicity). An
understanding of treatment capabilities for APTs has grown in recent years, though an understanding of site-specific loading of APIs will be influenced by a number of factors. The most comprehensive study to date was commissioned by American Water Works Association Research Foundation
(Snyder et al. 2007). During this study, various treatment technologies were evaluated singularly
and in combination for their efficiencies in removing select APIs, PCPs, and endocrine-disrupting
compounds.
Snyder et al. (2007) concluded that conventional processes for coagulation, flocculation,
sedimentation, and ultraviolet radiation (for disinfection) were largely ineffective for many of the
target analytes examined, including a number of APIs. More advanced treatment technologies such
as reverse osmosis, activated carbon, advanced oxidation processes, and nanofiltration were considered relatively highly effective for target analytes, though API structural properties influenced
treatability among tested technologies (Snyder et al. 2007). This study highlighted the importance
of understanding ecological risk from specific APIs prior to making risk-based management decisions (U.S. EPA 1999), because risk mitigation technologies such as advanced treatment processes
for APIs may be cost-prohibitive for municipal dischargers.
In developing countries, however, advanced WWTP technologies might not be employed, regulatory guidelines not be developed, or enforcement of regulations may not be as prevalent as in the
developed world. A recent study by Larsson et al. (2007) examined select APIs in effluent from a
WWTP in Patancheru, India. This WWTP was reported to primarily receive influent wastewater
from approximately 90 pharmaceutical manufacturers. Although isotope dilution was not employed
and extraction efficiencies were not reported in this screening study, high levels of several APIs were
reported in grab samples collected on two consecutive days, ranging from 90 (ranitidine) to 31,000
(ciprofloxacin) flg/L. Further, 21 of 59 target pharmaceuticals were reported earlier to be I flg/L
(Larsson et al. 2007). Levels of most of these APTs represent the highest concentrations reported
in the peer-reviewed literature, highlighting the importance of understanding site-specific ecological exposure and risks in less developed countries. A follow-up study (Fick et al. 2009) revealed
concentrations of APTs surface- and well-water levels that may be the highest yet reported in the
ambient environment-above the ppm (mg/L) level. Lakes receiving treated wastewater effluent
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contained ppm levels of three f1uoroquinolone antibiotics (ciprofloxacin, norfloxacin, and enoxacin) and cetirizine, an antihistamine. These studies show that in special cases, aquatic exposure
levels have the potential to reach concentrations that exceed human plasma levels achieved during
therapeutic treatment.

8.3.3

SITE-SPECIFIC

pH

AND

API pKA

Many APIs are weak acids or weak bases. Because these compounds are ionizable, their pKa and
the pH of the medium influence the proportion of the molecules present in a non ionized form. The
nonionized/ionized ratio of an API in a matrix (e.g., body compartment) is an important consideration in pharmacology and toxicology-influencing absorption and disposition profiles of APIs
following dosage in target organisms (Klaassen and Watkins 2003). As noted earlier, additional
uptake mechanisms are possible for APIs, but the nonionized form of a drug is more nonpolar and
thus considered to passively cross membranes more readily than the ionized form of an API (Kah
and Brown 2008). Such observations for APIs are included in physiological-based pharmacokinetic
models, which are discussed in greater detail later.
For conventional contaminants, such as pentachlorophenol and ammonia, the more nonionized form is believed to be more bioavailable and toxic to aquatic life. Subsequently, the U.S.
EPA developed National Ambient Water Quality Criteria for ammonia (U.S. EPA 1985) and
pentachlorophenol (U.S. EPA 1986) that incorporate adjustment factors for site-specific differences in pH. Similarly, the non ionized forms of APIs are likely more bioavailable and potentially
more toxic to aquatic life residing in receiving systems (Kah and Brown 2008). An example is
provided in Figure 8.2 for the SSRIs f1uoxetine (Figure 8.2a) and sertraline (Figure 8.2b), which
were reported in three fish species in a receiving system with in-stream pH commonly >8.0
(Brooks et al. 2005).
For chemicals that can ionize, distribution into lipid is a function of the pH. For these dissociative
systems, a "distribution" coefficient "D" (as opposed to partition coefficient) is calculated; D can be
viewed as an "apparent" partition coefficient-one that depends on pH and the degree of ionization.
Both f1uoxetine (pKa = 10.05 ± 0.10) and sertraJine (pKa =9.47 ± 0.40) are weak bases with log D
values and associated BCFs that are predicted to increase over environmentally relevant pH ranges
(Figure 8.2); however, the liposome-water distribution coefficient (log D 1ipw) may be more useful
than log D for predicting accumulation of ionizable compounds (Escher et al. 2000).
As presented previously, Nakamura et al. (2008) observed f1uoxetine toxicity for, and BCFs in,
Japanese medaka to increase with increasing pH in laboratory studies. Valenti et al. (2009) reported
similar toxicity-pH observations with juvenile fathead minnows exposed to sertraline. Further,
Valenti et al. (2009) performed a time-to-death fathead minnow study with 500 Ilg/L of sertraline,
and estimated associated LT50 values of >48,31.9, and 4.9 h at pH treatment levels of 6.5, 7.5, and
8.5, respectively. Such observations support the findings of Nakamura et al. (2008) because if more
non ionized sertraline exists at higher pH treatment levels, then sertraline should be more bioavailable and more readily absorbed by juvenile fathead minnows, resulting in the observed more rapid
onset of mortality at increasingly higher pHs.
Nakamura et al. (2008) further used pH and the BCF values calculated in their study to predict
aqueous f1uoxetine levels in Pecan Creek, TX that would result in reported levels of accumulation
of f1uoxetine in fish (Brooks et al. 2005). Interestingly Nakamura et al. (2008) imputed that the
f1uoxetine concentrations in Pecan Creek, TX should be -11 ng/L, which is representative of flu oxetine levels routinely observed in Pecan Creek over the past few years (Brooks unpublished data).
However, these estimates do not account for other routes of exposure such as diet. Brooks et al.
(in preparation) have quantitated levels of sertraline, norsertraline, f1uoxetine, and norfluoxetine in
periphyton and benthic macroinvertebrates from Pecan Creek, suggesting that future studies should
understand the relative contribution of bioconcentration to bioaccumulation of these and other APls
in aquatic life.
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FIGURE 8.2 Bioconcentration factors and log D values for the selective serotonin reuptake inhibitors
f1uoxetine (a) and sertraline (b) across environmentally relevant pH ranges. Values calculated using Advanced
Chemistry Development (ACD/Labs) Software VS.l4.

8.3.4

ADVANCEMENT IN TISSUE SAMPLING AND SURROGATE MONITORING

Site-specific exposure may be estimated in situ using surrogate measures of API bioavailability.
Passive sampling devices have long been used for obtaining estimates of aquatic uptake; see overviews in Greenwood et a1. (2007). A variety of devices have been developed for field-deployment
to emulate the uptake of xenobiotics by fish via diffusion into lipid. These include semipermeable
membrane devices (SPMD) (Barber et a1. 2006) and the polar organic chemical integrative sampler
(POCIS) (Vermeirssen et a1. 2005). Bayen et a1. (2009) discuss the variables in the use of passive
sampling devices for predicting uptake of hydrophobic chemicals, which would be applicable to
only a portion of APIs. Key characteristics for the device and organism are surface-to-volumel
weight ratios.
Nonlethal sampling via biopsy has been used for other pollutants but not yet for APls. One
example is the acquisition of tissue samples from fins (Rolfhus et a1. 2008).
Conventional sampling devices and tissue sampling approaches suffer from cost for the devices
and expenses associated with sample preparation, including organic solvents (and disposal) and
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analyst time. More significantly, with respect to exposure studies, tissue extraction usually only
measures total levels of the analyte as opposed to free, unbound residues that are more readily bioavailable. A recently developed approach uses in-vivo sampling by way of implanted fibers coated
with the sorbent poly(dimethylsiloxane) in a SPME format (Zhou et al. 2008); another approach
for establishing chemical activity in tissues is the silicone membrane equilibrator developed by
Mayer et al. (2009). SPME avoids many of these limitations and serves to collect only free residues. However, an understanding of the utility of various SPMDs, SPMEs, and POCIS technologies
across API classes ranging in physiochemical properties under varied environmentally relevant pH
ranges is not available at this time.

8.4

8.4.1

MODELS FOR PREDICTING EXPOSURE AND POTENTIAL EFFECTS OF APls
BACKGROUND AND PRIORITIZATION

Although several recent book chapters reviewed approaches for predicting human API (Versteeg
et al. 2005) and veterinary API (Metcalfe et al. 2008) concentrations in aquatic systems, limited
approaches are available for predicting exposure within an organism and linking exposure to potential ecological effects. Prospective assessments often include trigger values for further testing based
on predicted environmental concentrations (e.g., 1 f./g/L for human APIs in the United States). These
predicted concentrations are often driven by production volumes and associated patient uses, and do
not consider API potency. Ankley et al. (2007) reviewed assumptions associated with API trigger
values based on usage, noting that a trigger value of 1 f./g/L equates to a production volume in the
United States of 44,000 kg/year, but that this approach is not appropriate for highly potent APIs
such as EE2. Despite its very low production volume, it is highly potent (Cmax is less than 100 pg/mL,
where Cmax is the maximum plasma level reached during therapeutic dosing) and lipophilic (log
P - 4).

Because APIs represent compounds with a wide range of potencies and physiochemical properties (log P or D, pKa), screening approaches that examine similar properties for the large expanse
of thousands of APIs may be useful for prioritizing substances for further bioaccumulation or ecotoxicity studies. Although risk-based prioritization approaches have been developed for veterinary
APIs (Boxall et al. 2003, Capleton et al. 2006, Koois et al. 2008) and pesticide transformation
products (Sinclair et al. 2006), few approaches have been published for prioritizing human APIs
(see Gunnarsson et al. 2008, Kostich and Lazorchak 2008). A powerful tool for such studies may be
derived from probabilistic hazard/risk assessment. Chemical toxicity distributions (CTDs) represent
robust probabilistic approaches for predicting a specific toxicological response in a model organism
(e.g., fathead minnow reproduction) associated with the universe of chemicals that share a common MOA. CTDs are derived by plotting toxicity property data (e.g., NOAELs for fathead minnow
reproduction) for a number of chemicals against a probability scale. This represents an approach
conceptually similar to SSDs, which plot a distribution of toxicity benchmarks for various species
exposed to a common chemical. Much like SSDs, which allow an assessor to estimate the concentration below which a certain percentage of aquatic species would respond to a chemical (e.g., an
HC5 or 5th centile value), a CTD allows for predictions of the concentration below which a specific
percentage of chemicals with a common MOA (or theoretically any other common data property)
will still elicit a specific response (e.g., below the NOAEL for fathead minnow reproduction). For
example, CTDs were previously demonstrated to predict toxicity of carcinogens (Munro 1990), antibiotics (Brain et al. 2006), estrogen agonists (Dobbins et al. 2008), and the antimicrobial parabens
(Dobbins et al. 2009). This approach is particularly useful for environmental contaminants such
as APIs that have limited environmental exposure information (Brain et al. 2006, Dobbins et al.
2(09). CTDs were further demonstrated to exhibit diagnostic capabilities to predict differences in
sensitivities among common in vitro and in vivo models of estrogen agonist activity (Dobbins et al.
200S). CTDs are conceptually similar to but provide a more quantitative approach than Threshold
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of Toxicological Concern methodologies (Gross et al. 2010) previously used in human health risk
assessment (Brooks et al. 2009a).
We explored the utility of using probabilistic therapeutic distributions (PTDs), which are identical to
CTDs with the exception being that therapeutic plasma data (Cmax ) are examined, to represent the full
spectrum of API potencies. Figure 8.3 presents a PTD of Cmax values for 275 human APIs, and Table 8.5
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FIGURE 8.3 Probabilistic therapeutic distribution (PTD) of human plasma e max values for 275 Active
Pharmaceutical Ingredients (APIs; r2 = 0.99). For APIs with multiple e max values, distribution values are e max
concentrations associated with the most common dosage; also see Table 8.5.

TABLE 8.5
Probabilistic Therapeutic Distribution
Centiles and Predicted Cmax Values Derived
from Cmax Plasma Concentrations for 275
Human Pharmaceuticals; also See Figure 8.3
Centile Value

em., (jJg/ml)

1%

0.0001169

5%

0.00107

10%
25%

0.00347
0.0248

50%
75%

0.221

90%

1.97
14.15

95%
99%

419.32

45.97
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identifies concentrations associated with specific centiles (e.g., 5th, 95th centile) of the distribution. Using
this PTD approach ~ 25% of human APls are predicted to have Cmax values less than 0.0248 or greater
than 1.97 flg/mL (Table 8.5). Chemical classes with relatively high potencies include endocrine active
substances (n = 12; range: 0.0000922-0.0595 flg/mL), whereas NSAIDs (n = \1; range: 0.705-110 flg/
mL) have relatively lower potencies.
Although the PTD approach presented here only examined Cmax values to compare relative
potencies among a wide range of APls, PTDs could be developed for other API property data
useful for predicting accumulation (e.g., BCF). For example, maximum log D (or log K 1ipw) values
for weak acids and weak bases could be examined over an environmentally relevant pH range
(e.g., pH 6-9). Maximum log D PTDs could be developed for weak acids and weak bases (e.g.,
pH 9 used for a weak base with a pKa > 9) to predict the proportion of APIs that may be expected
to have log D values greater than some screening threshold (e.g., -3) at environmentally relevant
conditions. Such approaches could provide useful rankings of relative therapeutic property data and
for predicting potential property data of new medicines within API classes (Brooks et al. 2009a).
For example, Berninger and Brooks (2010) provide a more extensive examination of the utility of
PPDs. Specifically PPDs to prioritize pharmaceutical classes for further study, based on a statistically significant relationship between a mammalian margin of safety corollary and fish acuteto-chronic ratios, when fish chronic responses were plausibly linked to therapeutic MOA (Berninger
and Brooks 2010).

8.4.2

PHYSIOLOGICAL-BASED PHARMACO(ToXICO)KINETlC (PBPK) MODELS

Pharmacokinetics often utilizes one- and two-compartment models to examine potential systemic
effects following exposure. These relatively simple approaches model the distribution of a contaminant (or therapeutic) in a whole body or plasma compartment (one compartment). In a twocompartment model, disposition in a whole body or plasma compartment is coupled with a second
compartment, which represents movement to storage depots (e.g., fat) or metabolism. Although
these models are useful for deriving parameters such as clearance rates, multicompartment PBPK
models are also useful tools for predicting uptake and disposition of environmental contaminants.
These more advanced models can: incorporate physiological processes to predict distribution of a
compound among various tissues; extrapolate among organisms, exposure routes and ages; and estimate internal dose (Andersen and Dennison 2002, Barton et al. 2007). Subsequently, PBPK models
are routinely used in human health risk assessments (US. EPA 2006) and increasingly developed
for ecotoxicological applications in fish models (see other chapters in this book).
Whereas a number of investigators have examined the utility of physiological models for predicting environmental contaminant uptake and distribution in fish (Erickson et al. 2006a, 2006b, 2008),
Erickson et al. (2006a), recently developed a model in trout for describing uptake and elimination of
ionizable organic chemicals (chlorophenols) at fish gills. Erickson et al. (2006b) further applied this
model to several weak acids with pKa values ranging from 4.74 to 8.62 and log Kow values ranging
from 2.75 to 5.12. This model was found to predict uptake of ionizable chemicals based on physiochemical properties under the exposure conditions evaluated with trout (Erickson et al. 2006b).
Similar approaches with APIs would be useful for predicting uptake. Although multicompartment
PBPK models have not been developed for ionizable APIs and fish, such efforts could be critical to
estimate internal dose of APIs to target tissues under environmentally realistic API exposures and
pH gradients. This area deserves additional study to characterize API exposure in various tissues of
aquatic organisms where therapeutic targets are present.

8.4.3

THE HUGGETT MODEL

In addition to exhibiting wide ranges in potency, lipophilicity of APIs demonstrates marked
variability along a polar-nonpolar continuum. Accounting for such differences in lipophilicity and
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potency, Huggett et al. (2003) proposed the following model to prioritize human APIs for additional
chronic testing (Equation 8.l):
FssPC

= EC X (PBloodWater)

(8.l)

where FssPC is predicted fish steady-state plasma concentration, EC is the aqueous exposure
concentration, and P Blood:Watcr is the predicted partition coefficient in blood from aqueous exposure medium. Fish were selected for model development because more information is available for
these organisms, and fish appear to contain relatively high evolutionary conservation of API targets (Huggett et a1. 2003, Gunnarsson et al. 2008). The Huggett Model (Huggett "mammalian-fish
leverage model") simply proposes that the higher an API's predicted plasma concentration in fish
(FSSPC) compared with that of a mammal (e.g., human therapeutic plasma concentration [HTPC]
or a Cmax value) the higher the likelihood of chronic adverse effects (Huggett et al. 2003). As the
effect ratio (ER) (Equation 8.2) inflates, the likelihood of an API causing chronic effects drops. As
the ER drops, and especially when it becomes less than 1, adverse effects become more probable.
(8.2)
The core calculation of this model (PBloodWatcr) employed an empirical relationship between
log Kow and plasma concentrations in trout and in vitro partitioning data, which was developed for
hydrophobic compounds by Fitzsimmons et al. (2001; Equation 8.3):
log PBlood:Water = 0.73 x log Kow ~ 0.88

(8.3)

Though Huggett et a1. (2003) used Equation 8.3 for development of Equation 8.2, another relationship (Equation 8.4) reported by Fitzsimmons et al. (2001) appears even more important for APls
with apparent log P values lower than 2:
log

PBW

= log [(100 711ogKow x 0.16) + 0.84J

(8.4)

To derive Equations 8.3 and 8.4, Fitzsimmons et a1. (2001) coupled in vivo log PBloodWater values
for compounds having log K.,w values ranging from 3.1 to 8.2 with previously published in vitro data
for compounds with lower log Kow's (Bertelsen et al. 1998).
Brooks et a!. (2009a) extended this approach for fish exposed to veterinary medicines
(Equation 8.5):
(8.5)

where EICPlasma is the concentration in fish plasma resulting from environmental exposure. Similar
to the Huggett Model, the EICPlasma value proposed by Brooks et a!. (2008) would include an uptake
prediction from aqueous exposure, and Cmux would be derived from animal efficacy studies (e.g.,
in livestock). As previously noted, the study by Fick et al. (2010) identified accumulation of select
pharmaceuticals approaching or exceeding human therapeutic levels in plasma of caged fish below
effluent discharges.
It is important to note, however, that the models of Huggett et al. (2003) and Brooks et al. (2009b)
considered neither bioaccumulation through dietary sources nor the metabolism potential once an API
is absorbed into the fish. They also did not include log D in model derivation. Despite its limitations, the
Huggett Model appears to provide a reasonable screening approach that is amenable to further refinement. Remaining to be determined is whether: (i) a relationship similar to the equation of Fitzsimmons
et al. (2001) (Equation 8.3) would be appropriate for ionizable APIs if, for example, log Kow were
substituted with log D; (ii) dietary exposure is a concern for specific APIs; (iii) clearance rates could be
predicted in fish using mammalian or target organism information and allometric scaling approaches
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(if the metabolic pathway for eliminating an APT [e.g., CYP450 isoenzyme] is present in a study species); or (iv) API target densities and functional responses would be different between mammals and
fish. Similar approaches have not been developed for other organisms (e.g., invertebrates).

Summary
The preponderance of studies published on APIs as contaminants in the aquatic environment
have focused on establishing the presence of APIs in the abiotic environment-primarily levels
in water and sediment. Comparatively few studies document tissue concentrations. Even fewer
studies examine bioaccumulation from sediments. This is a major limitation in being able to
establish correlations between biological effects observed in the field with exposure, especially
because exposure usually involves multiple chemical (and other) stressors acting in unison or
in sequence. This is a critical step in being able to establish cause and effect. Few data are
available on tissue levels from free-ranging, migratory fish in locales not directly impacted by
sewage effluent. Even fewer controlled exposure studies follow the emergence of any type of
biological effect. As one example, a range of effects have been reported for trout chronically
exposed to a minimum of 500 ng/L of diclofenac for 21 days (Mehinto et al. 2010).
As part of the EPA's National Rivers and Streams Assessment (NRSA) study (U.S. EPA
2008b), plans include analysis of water and fish fillets from 183 urban rivers in the United States
for 54 APIs targeted from a range of therapeutic classes, as well as for four synthetic musks and
two of their metabolites (Blocksom et al. 2009). The NRSA will attempt to provide the largest
dataset yet on the occurrence of multiple APIs in fish tissue. Sample collection began in 2008,
and plans are to report on the data by 201l.
A concerted effort is needed to synthesize the data and knowledge that have already been
published, especially in the non-English literature not covered in this review (Daughton 2009).
This knowledge basically languishes in the published literature, reducing the ability to rationally prioritize and design the most needed research. As such, it is also unable to prevent duplication of effort. While actual empirical data on BCFs or tissue levels of APTs are extremely
scarce, a range of modeling techniques can be used to prioritize APIs according to predicted
BCF or known tendency for active transport. A limited list of APIs could then be targeted for
in-field monitoring to corroborate predictions. Computed BCFs from models are more available than empirical BCFs, but these have never been compiled in any database. Further, BAFs
(and BSAFs) for APIs should be further considered to account for site-specific pH influences
on ionization and partitioning, dietary exposures, and potential trophic transfer. The literature
focusing on veterinary drug use in aquaculture, although limited primarily to antibiotics and
steroids, may be of use in extrapolating to the ambient environment.
Predictive models and studies under controlled laboratory conditions directed at APIs that
have yet to be identified in aquatic tissue from the wild could be more widely used to better
inform the prioritization of APTs for field biomonitoring. For example, the fact that some synthetic progestins (i.e., levonorgestrel and 19-norethindrone) have a high affinity for fish sex hormone-binding globulin, points to the possibility that their enhanced uptake could lead to their
being found in tissues. Observations by Fick et al. (2010) for levonorgestrel appear to confirm this
perspective. This is critical because synthetic progestins have been identified to adversely affect
fish reproduction at low or even sub-part-per-trillion concentrations (Zeilinger et al. 2009).
More study is needed on the bioaccumulation of metabolites, especially those that are bioactive themselves. Likewise, more needs to be known about halogenated DBPs, which might
very well have higher BCFs than their parent APIs. Such data are important with regard to
trophic chain transfer and accumulation and with respect to human consumption, particularly
in effluent-dominated or dependent ecosystems. Given the probably significant role in medicine
to be played by nanomaterials (especially in better targeting drug delivery), studies are needed
on the uptake of engineered nanoparticles; see overview by Baun et al. (2008).
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Exposure studies under controlled laboratory conditions need to use concentrations that
have relevance to the environment. Earlier studies (as late as the 1990s) focused on acute toxicity studies, yielding results using concentrations that far exceeded realistic ambient levels.
Concentrations that occur in the aquatic environment are often orders of magnitude lower than
those used in many controlled studies. Such low concentrations are capable of eliciting sublethal
effects that are much more difficult to detect, especially those leading to subtle behavioral
effects or changes that are of delayed onset. Further studies relating tissue-specific internal
exposures to sublethal responses predicted by API MOAs are warranted.
Perhaps the gold standard for the study of exposure is the "lossless" model using radiolabeled
APIs. This permits attempts at achieving mass balance closures for residues distribution over
the whole body (e.g., Junker et al. 2006) and in target tissues where therapeutic targets for many
APIs are present at highest densities. Even with radiolabeled materials, however, it is rare that
mass balances can be fully achieved (Roffey et al. 2007). Unfortunately, radiolabeled APIs are
expensive and not widely available, presumably precluding such studies to date.
A major question is whether measurements of whole body or of certain tissues or compartments accurately reflect the internal dose at target organs better than exposure measurements
imputed from aqueous concentrations. While assumed to better represent exposure than do
concentrations external to the organism, the actual bioavailability of these residues is essentially
unknown. Given the exposure continuum that ultimately leads to stressor-receptor interaction,
stressor residues residing in tissues such as fat depots, cartilage, bone/scale, gonads, and blood
may not yet have reached their ultimate destinations where maximal biological activity can be
affected. New approaches using biopsy or in vivo equilibrative extraction of target tissues could
illuminate this unknown. As an example, SPME has been used to examine in vivo the body/tissue concentrations of free stressors (Wen et al. 2006, Zhou et al. 2008). Other new approaches
for measuring tissue concentrations include caudal fin biopsy (e.g., Rolfhus et al. 2008).
The difficulty in assessing tissue concentrations is the driving force behind the development
of physical model systems that can emulate biological exposure. A number of approaches have
evolved, primarily aqueous sampling devices that act as surrogates for whole-body exposure (to
estimate concentrations within the body). These devices include SPMD, SPME, and POCIS.
However, the utility of such technologies to be predictive of accumulation in organ systems within
an organism where API targets are present is not understood. Coupling radiolabeled API studies
with development of PBPK fish models presents a useful approach for future efforts, particularly
for understanding uptake of ionizable APIs across environmentally relevant pH gradients.
Perhaps the ultimate question is whether the assessment of exposure is truly meaningful if the
"totality" of exposure is not considered-that is, all the stressors to which an organism is exposed,
both anthropogenic and naturally occurring. This includes the universe of chemical stressors and
the numerous other stressors, including those that are physical, electromagnetic, radiological, or
biological. Relative risks of APls for aquatic organisms in the field, compared with other stressors, remains a significant research need. Perhaps the major question with regard to APIs in the
aquatic environment is the importance of long-term, low-level, multistressor exposure.
A range of other gaps and limitations with respect to better understanding APIs in aquatic
organisms is summarized in Table 8.6.
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TABLE 8.6
Tissue Levels of APls in Fish: limitations, Gaps, and Unique Aspects
limitation of Data

Example/Explanation

Additional Details

Of the thousands of publications covering the many
aspects of APIs as environmental contaminants, only
about 50 published studies have reported API
concentrations in fish tissues.
Ecotoxicity studies of APIs have been conducted to
assess effects endpoints. They generally provide
little data or insights regarding either the parameters
involved with internal exposure or tissue
concentrations.

Only a subset of these studies has
reported residues in fish exposed in
wild, native environments.

Linkage between
tissue residues and
biological effects

Do concentrations in aquatic tissues better represent
the potential for toxicity than concentrations free in
the surrounding aquatic environment? Do they better
reflect the actual dose? Tissue residues in target
systems could reflect relevant internal dose
compared to whole organism CBR approaches.

Very few studies have examined
internal dose (in plasma) following
exposure in the field.

Tissue data almost
always report total
concentrations

The portion of the total tissue-level of an API that is
bioavailable is almost always unknown; unknown
portions can be sequestered as adducts. Free versus
bound residues are rarely distinguished, likely
because radiolabeled APIs are scarce.

Total residue levels often involve
conjugates, which do not pose a
readily bioavailable source.

Limited scope of
targeted anal ytes

Extremely few APIs have been targeted for tissue
analysis. Empirical tissue levels in nonaquacultured
fish have been published for roughly only 30
different APIs, excluding antibiotics (roughly only
20 in samples from native environments); the vast
majority of all possible APls identified in the aquatic
environment (and those not yet identified) have
never been targeted for tissue analysis.

The limited published data for tissue
residues are focused primarily on
antibioticslbiocides and natural and
synthetic sex steroids; very few
studies have targeted the
simultaneous presence of multiple
APls.

Exposure
concentration
verification in
laboratory studies

With aqueous exposure under controlled conditions,
the actual dosage needs to be measured; the nominal
added dosage is likely to be different than the
measured dosage (as a result of sorption to container
walls and other solids, degradation, etc).

Inaccurate exposure concentrations
can lead to calculated BCFs that are
too high or too low by one or more
orders of magnitude.

Exposure duration and
frequency

Little is known regarding the life-cycle body
burden of APIs. Multigenerational studies are
extremely rare.
APIs with the lowest MDLs have the best chance of
being detected. Those with the highest MDLs have
the lowest chance of being detected. API MDLs for
a particular tissue can vary by more than 2 orders of
magnitude. This means that APls commonly present
in tissues but having high MDLs might not be
detected.
API residues have been reported in a wide range of
tissues. They are also nonnaliICed on ditlerent bases
(e.g" wet weight, dry weight, lipid content. etc.).

Multiyear monitoring studies are even
rarer (e.g., Boehmer et al. 2004).

Limited data on tissue
concentrations

Ecotoxicity studies
rarely report tissue
occurrence of APIs

Self-biasing

Tissue and
measurement basis

Tissue concentrations below
0.1-1 f./g/kg are rarely reported
because this usually is below the
method limit of detection-because
of matrix interferences. So an
unknown number ofAPls could be
present at these levels.
This makes intercomparisons between
studies very difficult.
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TABLE B.6 (continued)
Tissue Levels of APls in Fish: Limitations, Gaps, and Unique Aspects
Limitation of Data

Example/Explanation

Mass balance

Few studies attempt to achieve mass closure around
the total body burden of APls and their distribution
across all tissues.

Endogenous
contributions

For the endogenous sex steroids, levels metabolically
synthesized are augmented by unknown levels
contributed by uptake of exogenous residues in
water and sorbed to food.
The vast preponderance of bioconcentration studies
for fish has been conducted because of the concern
for food residues resulting from API usage in
aquaculture. Knowledge gained from these studies
could possibly be evaluated for relevance to
exposure in the ambient environment.

Veterinary medicine
exposure studies

Additional Details
Rigorous closure studies usually
require the use of radiolabeled APIs,
but the commercial availability of
radio labeled compounds is extremely
limited.
Exogenous contributions, even for
endogenous steroids. can have
origins from pharmaceuticals.
Aquaculture studies comprise two
major scenarios: (I) direct
incorporation of API in fish being
treated with high levels during
aquaculture, and (2) indirect
incorporation of API in wild fish that
become exposed to aquaculture
residues leftover from uneaten feed
and excreted residues.
Even in native environments, exposure
studies are often controlled by using
caged wild fish. More studies are
needed using fish captured from
waters less dominated by sewage
effluents.

Controlled exposure
studies versus
real-world settings

Tissue data are primarily obtained under controlled
exposure studies. Of the very limited studies on
tissue concentrations, only about two-thirds have
been obtained under ambient conditions with fish in
their native environments.

Real-world exposure
scenarios and
exposure
concentrations

Tissue data obtained under controlled conditions are
often derived from exposure concentrations far
higher than those that occur in native environments.
Controlled exposure studies often use exposure
concentrations that are one or more orders of
magnitude higher than those that exist in the ambient
environment, to maximize the chances of detecting
and quantifying any amounts that have been
accumulated.

BCFs usually drop off as exposure
concentrations increase, leading to
gross underestimates for real-world
settings at much lower
concentrations.

Inadequate uptake
models

Lipid-solubility (e.g .. as modeled by octanol-water
coefficient) is an inadequate predictor of API uptake.
!\" coupled with pK, (log D. log K"pw) provides a
more realistic model.

Other mechanisms may be involved,
especially those involving active
transport, facilitating the uptake of
polar (ionizable) APls.

1\,. data unreliable

Published 1\,,, data are extremely variable, probably a
result of ionization and localized charges and
because of interaction with other ions.
Bioaccumulation of APls cannot currently be
modeled.

Models employed for predictions of
physicochemical properties
inherently vary.
Too many variables compared with the
conventional nonpolar pollutants
(e.g .. legacy POPs). whose
accumulation is dictated primarily by
lipid-solubility and metabolism is
minimal.

The metabolism of APls creates the potential for
bioconcentration of metabolites. some of which are
bioactive themselves.

Little is known regarding
pharmacokinetics of APls in fish or

Models for predicting
BAFs

Metabolites

other aquatic organisllls.
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TABLE 8.6 (continued)
Tissue Levels of APls in Fish: Limitations, Caps, and Unique Aspects
limitation of Data

Example/Explanation

Additional Details

Tissue depots/
reservoirs

It is poorly understood how APIs are stored and

Tissue levels are not
necessary for ad verse
effects

Important to note that internal exposure is not
necessary for an effect when tbe target organ is
external.
APIs are designed to minimize accumulation during
therapy in the body. Any build-up in aquatic tissue
could be important, regardless of how low the BCF
might be.

This is the case. for example, with
exposure of the lateral-line sensory
organ.

lnterspecies
extrapolations

Variance in uptake and pharmacokinetics of fish
species makes usefulness of extrapolations
questionable, requiring further investigation.

Comparative metabolism and other
potential applications of
pharmacological "read-across" are
largely unknown.

Surrogates for
bioconcentration

Sampling devices based on partitioning of analytes
from aqueous media (e.g., semipermeable
membranes) have not been calibrated for fidelity to
bioconcentration under varying field conditions and
do not account for bioaccumulation through dietary
routes of exposure.

Significant BCFs are
not necessary for
adverse effects

accumulate in aquatic organisms.

Mechanisms could include adducts
with DNA, pigments such as
melanin, and a wide array of
endogenous proteins (especially
those in plasma).
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